

CURRICULUM VITAE

Jürgen Venitz, M.D., Ph.D.

PERSONAL DATA

BIRTH DATE/PLACE:

CITIZENSHIP:

PRIMARY AND SECONDARY EDUCATION

ACADEMIC TRAINING

1974-1981

Medical Student, School of Medicine,
Universität des Saarlandes, Homburg/Saar, West Germany.

April 7, 1981

Graduation from Medical School,
Universität des Saarlandes, Homburg/Saar, West Germany.

May 8, 1981

Medical Board Accreditation as Licensed Physician to practice medicine (Staatliche Approbation als Arzt),
Gesundheits- und Sozialamt des Saarlandes, Saarbrücken, West Germany.

Jan. 30, 1986

Medical Dissertation in Physiology,
1. Physiologisches Institut der Universität des Saarlandes (Head: _____, Homburg/Saar, West Germany,
Major Advisor and Mentor:
Title: "Interaction of Local Anesthetics with the Sodium Channel of Striated Frog Muscle Fibers under Voltage Clamp Conditions: Comparison of Benzocaine and n-Alkanols" (magna cum laude).

1980-1984

Special College Courses in Computer Science (part-time),
Basic, Fortran, PL/1, Pascal, Algol
Fernuniversität Hagen, West Germany.

1991-1995

Special College Courses,
Principles of Psychological Measurements,

Drug Dependence,
Immunology,
Computational Biology,
Introduction into Molecular Modeling
Virginia Commonwealth University, Richmond, VA

PROFESSIONAL TRAINING AND EXPERIENCE

1980-1981

Medical Residency,

Internal Medicine, General Surgery and Anesthesiology
Knappschaftskrankenhaus Sulzbach/Saar and Quierschied/Saar, West Germany
Medical Directors:

1981-1982

Compulsory Military Service, Bundeswehr (German Armed Forces),
Flußpionierkompanie 800, Neuwied/Rhein, West Germany
Commanding Officer:

Last Rank:

Major (Medical Corps)

Staff Physician (General Practitioner) and Deputy Commanding Officer of an Army River Engineer Platoon; special training in diving medicine at the Schiffahrtsmedizinisches Institut in Kiel/Ostsee. Provided primary ambulatory and in-house medical care to soldiers of two engineer platoons including diving staff; supervised and trained medical and diving staff in the principles of diving medicine.

1982-1985

Staff Study Physician, promoted to Director of Clinical Research and Development,
Institut für Klinische Pharmakologie Bobenheim (Institute for Clinical Pharmacology, a Clinical Contract Research Organization), Grünstadt/Pfalz, West Germany
Medical Director and Mentor:

Design, organization, implementation and analysis of clinical pharmacological studies mainly in phase I and II; development of non-invasive pharmacodynamic models in human pharmacology (cardiovascular, gastrointestinal, CNS and NSAID drugs); responsible for the Medical Department including a forty-bed Clinical Pharmacology Research Unit, supervision of Staff Study Physicians, Research Nurses and paramedical staff; responsible for the Data Analysis Department to do computerized statistical data analysis; involved in training of graduate and medical students; served as external consultant to the local IRB and Scientific Advisory Board.

1985-1987

Postdoctoral Research Fellow,
The Beehive, College of Pharmacy, University of Florida, Gainesville, Florida
Advisor and Mentor:

Attended special graduate courses in analytical chemistry, chemical stability and kinetics, biopharmaceutics and received a rigorous training in pharmacokinetics; performed drug assay development (HPLC with UV, fluorescence, electrochemical detection), physicochemical and bioanalytical studies and pharmacokinetic studies in dogs and humans; coordinated weekly Graduate Student Research Seminars for the Department of Pharmaceutics.

1988-1989

Research Assistant Professor
Department of Pharmacy and Pharmaceutics, School of Pharmacy, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia
Development of a Pharmacodynamic Research Laboratory and a Clinical Pharmacology Research Unit in collaboration with _____; active teaching in the undergraduate, Pharm.D. and graduate teaching programs.

1988-1990

Medical Director, BioPharm Center for Clinical Research,
School of Pharmacy, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia

1989-1990

Medical Director, BioClin Inc., Richmond, Virginia

1989-1994

Assistant Professor, Department of Pharmacy and Pharmaceutics,
Director, Pharmacokinetics/Pharmacodynamics Research Laboratory,

1994-present

Associate Professor with Tenure, Department of Pharmacy and Pharmaceutics,
Director, Pharmacokinetics/Pharmacodynamics Laboratory,
Co-Director, Virginia Commonwealth University Institute for Clinical Trials
Interim Vice Chair, Department of Pharmaceutics

1997-present

1999-present

Directing a departmental Pharmacokinetics/Pharmacodynamics Research Laboratory including computerized cognitive function, EEG and cardiovascular monitoring and testing equipment; developing novel experimental clinical pharmacological paradigms to assess pharmacokinetic-pharmacodynamic correlations for cardiovascular and CNS active drugs; designing, implementing and analyzing phase I entry-into-human safety and toleration, pharmacokinetic and pharmacodynamic studies; developing innovative data analysis approaches in QSAR, pharmacokinetics and pharmacodynamics; teaching and validating novel computerized mathematical pharmacokinetic/pharmacodynamic models. Teaching undergraduate pharmacy, Pharm.D., as well as pharmacy and nurse anesthesia graduate courses; design and implementation of computer-assisted, as well as World-Wide-Web-based teaching methods in pharmacokinetics on an undergraduate and graduate level; precepting of pharmacy students in their elective clinical research rotations; advising and mentoring of postdoctoral, full-time graduate and Pharm.D. students on their research projects.

Appointed to co-direct the VCU Institute for Clinical Trials in support of the administration and implementation of clinical trials at the VCU Medical Campus; assisting in the administration of the Department of Pharmaceutics.

Active as scientific consultant in clinical pharmacology (Pharmacokinetics and Pharmacodynamics, Phase I Clinical Drug Development) for several pharmaceutical companies and the Food and Drug Administration, Office of Clinical Pharmacology and Biopharmaceutics as member of expert panels and special government employee; service on multiple departmental, university-wide and national professional committees and organizations.

PAST AND CURRENT COLLABORATIVE RESEARCH INTERESTS


1992-1997	<u>Phase I Clinical Pharmacokinetics/Pharmacodynamics of Substance P (NK₁-Receptor) Antagonists</u>
1993-present	<u>In-Vitro, In-Vivo and Clinical Pharmacokinetics/Pharmacodynamics of Allosteric Modifiers of Hemoglobin as Novel Therapeutic Agents</u>
1994-present	<u>Use of Artificial Neural Networks in QSAR</u>
1994-present	<u>Phase I Clinical Pharmacology of Novel Oncological Agents</u>
1995-1997	<u>Phase I Clinical Pharmacokinetics/Pharmacodynamics of NMDA-Receptor Antagonists (in Neuroprotection)</u>
1996-present	<u>Clinical Pharmacokinetics/Pharmacodynamics of Ethanol and Nicotine</u>
1996-present	<u>Clinical Pharmacology of RSR13, a Hemoglobin Allosteric Modifier, as Potential Radiation Sensitizer</u>
1996-1998	<u>Pharmacokinetics/Pharmacodynamics of Novel Antisense Oligodeoxynucleotides</u>
1996-1997	<u>Phase I Clinical Pharmacokinetics/Pharmacodynamics of CRH-Receptor Antagonists (in Depression)</u>
1996-present	<u>Bioequivalence of Albuterol Metered Dose Inhalers</u>
1998-present	<u>PK/PD Simulations of IV Drugs Used in Anesthesia to Support an Anesthesiology Simulator</u>
	FL, Medical Education Technology (METI), Sarasota, FL.
1998-present	<u>Effect of Chronic Renal Disease on Drug Metabolism</u>

SPECIAL TRAINING AND PARTICIPATION IN CONTINUING EDUCATION PROGRAMS

1983	Introduction in Impedance Cardiography _____, Methodist Hospital in Indianapolis, IN.
1984	Seminar on Statistical Analysis in Life Sciences _____, Klinikum Grosshadern, München, West Germany.
1988-1997	ACLS-Provider/CPR Certification, Medical College of Virginia, Richmond, VA.
1990	Seminar on HIV Test Pre- and Post-Test Counseling, Medical College of Virginia, Richmond, VA.
1991	Symposium on Animals in Biomedical Research and Teaching, Medical College of Virginia, Richmond, VA.
1991	AAPS Short Course, Convolution, Deconvolution and Linear Systems (_____)

- al.), Washington, DC, November 11, 1991.
- 1992 Short Course in Population Pharmacokinetic Data Analysis Using the NonMem System (~~_____~~ Rockville, MD.
- 1994 Clinical Pharmacology Review Workshop
ASCPT, New Orleans, LA, April 1 and 2, 1994.
- 1994 Pharmacokinetic/Pharmacodynamic Modeling Workshop (~~_____~~ Buffalo, NY, May 23-25, 1994.
- 1994 Short Course in Modeling and Data Analysis in Pharmacokinetics/Pharmacodynamics using Adapt II ~~_____~~
~~_____~~ Rockville, MD, July 28-29, 1994.
- 1994-1995 Minisabbatical in Population Pharmacokinetic Data Analysis
~~_____~~ Division of Biopharmaceutics, CEDR, Food and Drug Administration, Rockville, MD, July 1994 - July 1995.
- 1995 AAPS Short Course, Introduction to Artificial Neural Networks ~~_____~~ Miami Beach, FL, November 5, 1995.
- 1996 IBC Conference on Pharmacokinetic-Pharmacodynamic Analysis in Drug Development, Washington, DC, February 1-2, 1996.
- 1996 DIA Meeting on Assessing Safety of Investigational Drugs, Gaithersburg, MD, April 15-16, 1996.
- 1997 Georgetown Center for Drug Development Science Conference on "Modeling and Simulation of Clinical Trials in Drug Development and Regulation", Herndon, VA, November 10-11, 1997.

LANGUAGES



HONORS AND AWARDS

- 1990 **First Excellence in Teaching Award,**
awarded by the faculty, School of Pharmacy, MCV/VCU.
- 1994 **Member, Rho Chi Pharmacy Honor Society,**
elected by the faculty and students, School of Pharmacy, MCV/VCU.
- 1994 **Member, Sigma Delta Pi National Collegiate Hispanic Honor Society**
awarded by the faculty, Foreign Language Department.
- 1998 **Nomination,**
Virginia Council of Higher Education 1999 Outstanding Faculty Award; nominated by the VCU School of Pharmacy.
- 1999 **Nomination,**
Teaching Excellence Award, nominated by pharmacy students, School of Pharmacy, MCV/VCU.

PROFESSIONAL AFFILIATIONS

- 1981-present **Member, Bundesärztekammer (German Federal Board of Physicians), Köln, West Germany.**
- 1981-1992 **Member, Ärztekammer des Saarlandes (Regional Board of Physicians, Saarland), Saarbrücken, Germany.**
- 1982-1992 **Member, Ärztekammer Rheinland/Pfalz, Bezirksärztekammer Pfalz (Regional Board of Physicians, Rhineland/Palatinate), Neustadt/Pfalz, Germany.**

1984-present	Member, GMDs, Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie (German Society of Medical Informatics, Biometrics and Epidemiology), Köln, Germany.
1986-1991	Member, ACCP (American College of Clinical Pharmacology), Yorkville, NY.
1987-present	Member, AAPS (American Association of Pharmaceutical Scientists), Alexandria, VA.
1990-present	Member, AACP (American Association of Colleges of Pharmacy), Kansas City, MI.
1990-present	Affiliate Member, ACCP (American College of Clinical Pharmacy), Alexandria, VA.
1991-1993	Member, ACCP Chesapeake Chapter, (American College of Clinical Pharmacology).
1991-present	Fellow, ACCP (American College of Clinical Pharmacology), New Hartford, NY.
1992-present	Member, ASCPT (American Society of Clinical Pharmacology and Therapeutics), Conshohocken, PA.
1993-present	Member, AAAS (American Association for the Advancement of Science), Washington, DC.

ACADEMIC TEACHING EXPERIENCES AND RESPONSIBILITIES

1976-1979	Graduate Teaching Assistant, (<i>Peripheral Nerve Conduction, Ear Physiology, Cardiovascular Physiology</i>) Physiology Laboratory for Medical Students (by semester), Institute of Physiology, Universität des Saarlandes, Homburg/Saar, West Germany.
1982-1984	External Clerkship Preceptor, (<i>Experimental Human Pharmacology, Clinical Data Analysis, Good Clinical Practices</i>) Clinical Pharmacology Rotation for Medical Students (annually), Institut für Klinische Pharmakologie Bobenheim, Grünstadt, West Germany.
1986-1987	Co-Coordinator and Instructor, Graduate Pharmaceutics Research Seminar (by semester), Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL.
1988-1994	Coordinator and Instructor, (<i>Compartmental PK, Noncompartmental PK, Pharmacodynamics, Population PK</i>) Clinical Pharmacokinetics (PHA 622, annually) for Pharm.D. and graduate students, Department of Pharmacy and Pharmaceutics, MCV/VCU.
1989-1997	Instructor, (<i>Clinical Drug Development</i>) Advanced Biopharmaceutics (PHA 621, bi-annually) for graduate students, Dept. of Pharmacy and Pharmaceutics, MCV/VCU.
1989-present	Co-Coordinator and Instructor, (<i>Noncompartmental PK Analysis, Clearance Concepts, Physiologically-based PK, Pharmacodynamics, Nonlinear Regression, PK/PD Modeling</i>) Advanced Pharmacokinetics (PHA 624, PCEU 624, bi-annually) for graduate students (since 1997 offered as course on the World Wide Web), Dept. of Pharmaceutics, MCV/VCU. http://www.wcb.vcu.edu/wcb/schools/PHA/pha/jvenitz/12/index.html
1989-1996	Instructor and Co-Coordinator (1992 only), (<i>Pharmacodynamics, Dose Individualization in Renal Insufficiency and Hepatic Insufficiency</i>) Principles of Pharmacy (PHA 402, annually) for pharmacy BS students, Dept. of Pharmacy and Pharmaceutics, MCV/VCU.
1989-1992	Instructor, (<i>Clinical Trial Data Management</i>) Drug Literature Evaluation (PHA 650, annually) for post B.S./track-in Pharm.D. students, Dept. of Pharmacy and Pharmaceutics, MCV/VCU.
1990-present	Coordinator and Instructor, Pharmacokinetics/Pharmacodynamics Graduate Research and Journal Club (by semester), Dept. of Pharmaceutics, MCV/VCU.
1990-1998	Preceptor, (<i>Clinical Research Rotation</i>) Advanced Pharmacy Practice Elective Rotation (PHA 696, annually) for post B.S./track-in/bridge Pharm.D. students, Dept. of Pharmacy and Pharmaceutics, MCV/VCU.

- 1991-present **Instructor,**
(Basic Pharmacokinetics/Pharmacodynamics for Nurse Anesthetists) Medicinal Chemistry (PHC 532, annually) for M.S. Nurse Anesthetist students, Dept. of Medicinal Chemistry, MCV/VCU.
- 1995-present **Student Advisor, Tutor and Preceptor,**
Pharmacy Practicum over six semesters (PHA 557/558/657/658/757/758 by semester) for entry-level Pharm.D. students, Depts. of Pharmacy and Pharmaceutics, MCV/VCU.
- 1995-1997 **Instructor and Remedial Work Supervisor,**
(Introductory Biostatistics) Principles of Pharmacy I (PHA 503, annually) for entry-level Pharm.D. (P-1) students (since 1997 offered as course on the World Wide Web), Dept. of Pharmaceutics, MCV/VCU.
<http://www.wcb.vcu.edu/wcb/schools/PHA/pha/jvenitz/5/index.html>
- 1995-1996 **Coordinator and Instructor,**
(Compartmental PK, Clearance Concepts, Pharmacodynamics) Clinical Pharmacokinetics (PHA 622, annually) for Pharm.D. (bridge program) and graduate students, Dept. of Pharmacy and Pharmaceutics, MCV/VCU.
- 1995-1996 **Instructor,**
(Use of Artificial Neural Networks (ANNs) in Quantitative Structure-Activity Relationship (QSAR)) Drug Design (PHC 630, annually) for graduate students, Dept. of Medicinal Chemistry, MCV/VCU.
- 1996-present **Preceptor,**
(Clinical Pharmacology Research) Elective Clerkship (PHA 767, annually) for Pharm.D. (bridge and entry-level program, P-4) students, Depts. of Pharmacy and Pharmaceutics, MCV/VCU.
- 1997 **Instructor,**
(Bayesian Pharmacokinetics, Decision Analysis in Pharmacokinetics) Applied Pharmacokinetics (PHA 606, annually) for entry-level Pharm.D. (P-2) students, Dept. of Pharmacy and Pharmaceutics, MCV/VCU.
- 1996-present **Preceptor,**
(Clinical Research Experience) Pharmacy Practicum (PHA 558, annually) for entry-level Pharm.D. (P-1) students, Dept. of Pharmacy, MCV/VCU.
- 1997-present **Course Coordinator and Instructor,**
(Therapeutic Drug Monitoring, Pharmacodynamics) Clinical Pharmacokinetics (PHA 705, annually) for entry-level Pharm.D. (P-3) students (since 1997 offered as course on the World Wide Web), Dept. of Pharmaceutics, MCV/VCU.
<http://www.wcb.vcu.edu/wcb/schools/PHA/pha/jvenitz/11/index.html>
- 1997-present **Instructor,**
(Multiple and Nonlinear Regression), Drug Literature I (PHA 745, annually) for entry-level Pharm.D. (P-3) students, Dept. of Pharmacy, MCV/VCU.
- 1998-present **Instructor,**
(Pharmacokinetic/Pharmacodynamic Studies), Drug Literature II (PHA 746, annually) for entry-level Pharm.D. (P-3) students, Dept. of Pharmacy, MCV/VCU.
- 1998-present **Instructor (jointly taught with D. Abraham, Ph.D.),**
(Discovery and Clinical Drug Development of Allosteric Hemoglobin Modifiers), Integrated Sciences (PHA 739, annually) for entry-level Pharm.D. (P-3) students, Depts. of Pharmacy and Pharmaceutics, MCV/VCU.
- 1998-present **Co-Coordinator and Instructor,**
(Compartmental PK, Clearance Concepts, Pharmacodynamics) Clinical Pharmacokinetics (PHA 622, annually) for non-traditional, off-site Pharm.D. students, taught as course on the World Wide Web, Dept. of Pharmacy, MCV/VCU.
<http://views.vcu.edu/pha622>
- 1999-present **Instructor,**
(Drug Development Process) Medicinal Chemistry and Drug Design (PHC 310, annually) for chemistry and biology majors, Dept. of Medicinal Chemistry, MCV/VCU.
- 1999-present **Instructor,**
(Clinical Pharmacology and PK/PD Research) Elective Course (PCEU 691, annually) for entry-level Pharm.D. (P-3) students, Dept. of Pharmaceutics, MCV/VCU.

ACADEMIC ADVISING AND MENTORING RESPONSIBILITIES

1988-present

Co-Advisor and Member, Graduate Student Research Advisory Committee

1988-1988
1988-1989
1988-1990
1989-1992
1989-1992
1990-1994
1991-1995
1991-1995
1991-1995
1991-1996
1991-1996
1991-1996
1991-1996
1992-1996
1996-1997
1996-1997
1993-1998
1996-1999
1991-present
1993-present
1997-present
1998-present
1998-present
1999-present

1989-1994

Co-Advisor and Member, Pharm.D. Student Research Project Advisory Committee

1989-1991
1989-1991
1990-1992
1990-1992
1990-1992
1990-1992
1991-1993
1991-1993
1991-1993
1992-1994
1992-1994
1994-1996

1989-present

Principal Graduate Advisor, Mentor and Chair, Graduate Student Research Advisory Committee

1989-1992

1991-1995

1992-1995

1990-1996

1990-1997

1993-1997

1996-present

1996-present

1998-present

1989-1992

Principal Advisor, Mentor and Chair,
Pharm.D. Student Research Advisory Committee
1988-1990

1988-1990

1989-1991

1990-1992

1991-1993

1992-present

Faculty Advisor,
Undergraduate Pharmacy/entry-level Pharm.D. (P-1 through P-3) Students

1992-1995

1992-1994

1993-1994

1993-1995

1994-1995

1994-1996

1995-1996

1995-1998

1995-1998

1995-1998

1995-1998

1995-1998

1995-1998

1995-1998

1995-1998

1998-present

1998-present

1998-present

1998-present

1998-present

1998-present

1998-present

1998-present

1998-present

1998-present

1992-present

Postdoctoral Research Advisor and Mentor,
Clinical Pharmacology Research Fellows
1992-1993

1993-1995

1995-1999

1995-1997	
1998-1999	
1994-present	Undergraduate/Professional Student Research Advisor
	1994-1995
	1997-1999
	1998-present
1999-present	External Student/Visiting Scientist Host and Advisor
	1999

SERVICE ON UNIVERSITY, SCHOOL AND DEPARTMENTAL COMMITTEES

1989-1998	Member, Graduate Research Advisory Committee, Department of Pharmacy and Pharmaceutics.
1989-1995	Member, Pharm.D. Research Review Committee, Department of Pharmacy and Pharmaceutics.
1990-1995	Member, Pharm.D. Research Advisory Committee, School of Pharmacy.
1999-present	Member, Pharm.D. Research Advisory Committee, School of Pharmacy.
1990-1992	Co-Director, Computer Laboratory, School of Pharmacy.
1990-1993	Member, A.D. Williams Research Advisory Committee, Virginia Commonwealth University.
1990-1994	Member, Computer and Learning Resource Committee, School of Pharmacy.
1991-1996	Member, Pharmacy Teaching Excellence Award Committee, School of Pharmacy.
1991-1995	Member, Executive Committee on Research, Division of Clinical Pharmacy.
1992-1993	Member, Search Committee for Clinical Faculty Position in Pharmacy Practice, School of Pharmacy.
1992-1993	Alternate Member, Grievance Committee, School of Pharmacy.
1992-1993	Member, Search Committee for Graduate Faculty Position in Pharmaceutics, Dept. of Pharmacy and Pharmaceutics.
1992-1999	Member, Graduate Comprehensive Examination Committee, Dept. of Pharmaceutics.
1993-present	Dean's Representative, VCU Graduate School, on oral comprehensive and final defense examinations for Ph.D. candidates.
1993-1994	Member, Self-Study Committee for Standards on Faculty and Staff, School of Pharmacy.
1993-1994	Member, Self-Study Committee for the Doctor of Pharmacy Program, School of Pharmacy.

1994-1995	Member, Forbes-Day Proposal Faculty Review Panel, Virginia Commonwealth University.
1994	Member, Pharmaceutics Sequence Task Force (for Curriculum Review), Department of Pharmacy and Pharmaceutics.
1994	Member, Drug Literature/Statistics Sequence Task Force (for Curriculum Review), Department of Pharmacy and Pharmaceutics.
1994	Member, Task Force on Women in Drug Studies (WIDS), Advising the Committee on the Conduct of Human Research (CCHR), Virginia Commonwealth University.
1994-1996	Member,
1996-1997	Chair,
1997-1998	Member, Faculty Awards Committee, School of Pharmacy.
1995-present	Member, Information Technology Advisory Committee, School of Pharmacy
1996-1997	Member, Promotions Committee, First Year Bridge Pharm.D. Students, School of Pharmacy.
1996-1997	Member, Search Committee for Graduate Faculty Position in Pharmaceutics, Dept. of Pharmacy and Pharmaceutics.
1996-1997	Chair, Pharm.D./Ph.D. Program Development Committee, School of Pharmacy.
1996-1997	Member, Drug Interactions-Mapping Committee, Dept. of Pharmacy and Pharmaceutics.
1996	Chair, P-3 Students Promotions Committee, School of Pharmacy.
1996-1997	Chair, Pharmacy Teaching Excellence Award Committee, School of Pharmacy.
1997-present	Co-Director, (School of Pharmacy Representative) Clinical Trials Institute, Virginia Commonwealth University.
1997	Member, P-3 Students Promotions Committee, School of Pharmacy.
1997-1998	Member, Faculty Promotion and Tenure Committee, School of Pharmacy.
1998	Member, Faculty Promotion and Tenure Committee, School of Pharmacy.
1998	Member, Faculty Promotion and Tenure Committee, School of Pharmacy.
1998-present	Chair, Pharm.D./Ph.D. Steering Committee, School of Pharmacy.
1998	Chair, Faculty Promotion and Tenure Committee, School of Pharmacy.
1998-present	Member, School Faculty Promotion and Tenure Committee, School of Pharmacy.
1998	Member, Promotion and Tenure Committee, School of Pharmacy.
1998-1999	Member, Search Committee, Geriatrics Specialist, Dept. of Pharmacy, School of Pharmacy.
1999	Member, Search Committee, Informatics Specialist, School of Pharmacy.
1998-1999	Member, Subcommittee on Initiative II, Strategic Planning, School of Pharmacy.
1999-present	Chair, Faculty Promotion and Tenure Committee, School of Pharmacy.
1999-present	Member, School Promotion and Tenure Guideline Committee, School of Pharmacy.
1998-1999	Member, Search Committee, Chair, Division of Pharmacy Administration, Dept. of Pharmacy, School of Pharmacy.

SERVICE ON PROFESSIONAL AND SCIENTIFIC PEER REVIEW COMMITTEES

1989	Chair and Session Moderator, Podium Session, 18th Annual National ACCP (Pharmacology) Meeting, Baltimore, MD, October 11-14, 1989.
1990	Member, Organizing Committee, Chair and Session Moderator, Mini Symposium "Pharmacokinetic/Pharmacodynamic Modeling", 1st Annual Southeastern Regional AAPS Meeting, Charleston, SC, April 4-5, 1991.
1991	Member, Special Review Panel, Adult AIDS Clinical Trials Unit National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, November 19-22, 1991.
1992	Member, Organizing Committee, Chair and Session Moderator, Session "Clinical Testing of Aerosol Drugs", Respiratory Drug Delivery III Symposium, Williamsburg, VA, May 17-22, 1992.
1992-1996	Member, Organizing Committee, Annual Eastern Regional AAPS Meeting, New Brunswick, NJ.
1992-present	Member, Special Review Panel, Basic Sciences II Subcommittee, AIDS Research Review Committee National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD.
1993-1998	Member, Substance Abuse Committee, American Society for Clinical Pharmacology and Therapeutics (ASCPT).
1993-1994	Member, Organizing Committee, Annual Southeastern Regional AAPS Meeting, Durham, NC.
1994	Co-Chair and Session Moderator, PPDM Session "In-Vitro Drug Metabolism", 3rd Annual Southeastern Regional AAPS Meeting, Durham, NC, April 21-22, 1994.
1994-1995	Chair, PPDM Organizing Committee, Annual Eastern Regional AAPS Meeting, New Brunswick, NJ
1994	Co-Chair and Session Moderator, PPDM Session "Preclinical and Clinical Aspects of Drug Interactions", Annual Eastern Regional AAPS Meeting, New Brunswick, NJ, June 6-7, 1994.
1995	Co-Chair and Session Moderator, PPDM/CIS Joint Session "Women as Subjects of Clinical Trials", Annual Eastern Regional AAPS Meeting, New Brunswick, NJ, June 5-6 1995.
1995-1996	Member, AAPS Short Course Committee, Chair, Clinical Sciences Short Course Committee Annual AAPS Meeting, Miami Beach, FL; Seattle, WA.
1996	Co-Chair and Session Moderator, PPDM Session "Bioavailability/Bioequivalence of Nonabsorbed Drugs", Annual Eastern Regional AAPS Meeting, New Brunswick, NJ, June 5-6 1996.
1997-1999	Member, 1999 Annual Meeting Planning Committee, ACCP, Rockville, MD, September 16-18, 1999.
1997-present	Member, Projektgruppe "Pharmakokinetik-Pharmakodynamik" [Project Group: Pharmacokinetics / Pharmacodynamics], GMDS (German Society of Medical Informatics, Biometrics and Epidemiology), Köln, Germany.
1997-present	Member, Practice Research Network (PRN) "Pharmacokinetics and Pharmacodynamics", ACCP, Alexandria, VA.
1998	Member, International Scientific Advisory Committee, Clinical Pharmacology: Optimizing the Science of Drug Development AAPS/ASCPT/AACP/FDA/EUFEPS Conference, September 9-11, 1998, Washington, DC.

- 1998 **Session Moderator**, PPDM Poster Session,
13th Annual Meeting, AAPS, San Francisco, CA, November 15-18, 1998.
- 1998-1999 **Extramural Expert Scientific Proposal Reviewer** Office for Women's Health FY 1999, Food and Drug
Administration, Rockville, MD (invited by _____).
- 1999 **Symposium Moderator**, APQ/PDD Symposium, "CROs in Accelerated Drug Delivery",
Southeastern Regional Meeting, AAPS, Research Triangle Park, NC, June 21, 1999.

SERVICE ON REGULATORY AGENCY COMMITTEES

- 1996-1997 **Outside Expert** (Outside Expert, invited by _____), *Food Effect Guidance Working Group*,
Office of Clinical Pharmacology and Biopharmaceutics, CDER, Food and Drug Administration, Rockville,
MD.
- 1996-1999 **Member** (Outside Expert, invited by _____), *Liver Disease Guidance Working Group*, Office
of Clinical Pharmacology and Biopharmaceutics, CDER, Food and Drug Administration, Rockville, MD.
- 1996-present **Outside Expert** (Outside Expert, invited by _____), *PK/PD Implementation Guidance Working*
Group, Office of Clinical Pharmacology and Biopharmaceutics, CDER, Food and Drug Administration,
Rockville, MD.
Invited Expert, External Expert Panel Meetings on June 10, 1998 in Bethesda, MD and on September 8,
1998 in Arlington, VA.
- 1997-1998 **Member** (Outside Expert, invited by _____), *Renal Disease Guidance Working Group*, Office
of Clinical Pharmacology and Biopharmaceutics, CDER, Food and Drug Administration, Rockville, MD.
Invited Expert, External Expert Panel Meeting on February 18, 1997 in Rockville, MD.
- 1997-1999 **Member** (Outside Expert, invited by _____), *In-Vivo Drug-Drug Interaction Guidance Working*
Group, Office of Clinical Pharmacology and Biopharmaceutics, CDER, Food and Drug Administration,
Rockville, MD.
Invited Expert, Advisory Committee on Pharmaceutical Sciences (ACPS) Meeting on December 11-12,
1997 in Silver Spring, MD.
- 1997-present **Member** (Outside expert, invited by _____), *Narrow Therapeutic Index Drugs Working Group*,
Office of Clinical Pharmacology and Biopharmaceutics, CDER, Food and Drug Administration, Rockville,
MD.

OTHER SCIENTIFIC REVIEW OR EDUCATIONAL ACTIVITIES

- 1986, 1987 **Workshop Instructor**, *Pharmacokinetics Workshop* (E.R. _____),
St. Augustine, FL, April 1986,
St. Augustine, FL, April 1987.
- 1990-1994 **Reviewer**, *Pharmaceutical Research* (_____ editor).
- 1990, 1996 **Reviewer**, *Biopharmaceutics and Drug Disposition*, (invited by _____, editor)
- 1990 **Workshop Co-Organizer and Instructor**, *Therapia Workshop for Pharmacists in Industry, Academia,*
and Hospitals "Pharmacokinetics and Biopharmaceutics - Basics and Applications" (with _____,
Ph.D., U. of Florida),
Wiesbaden, Germany, October 29-31, 1990.
- 1991 **Reviewer**, *Journal of Pharmaceutical Sciences* (invited by _____, editor).
- 1992 **Workshop Organizer and Instructor**, *Short Course for Pharmacokineticists "Nonlinear*
Pharmacokinetics"
Pharmacodynamics Research Department, American Cyanamid Company, Medical Research Division,
Pearl River, NY, April 27, 1992 (invited by _____).
- 1993 **Book Reviewer**, Marcel-Dekker Publishers, New York, NY.
- 1993-present **Reviewer**, *Medicinal Chemistry Research, Med Chem Res* (invited by _____, editor).
- 1994-1998 **Abstract Reviewer** (Drug Metabolism and Pharmacokinetics Section),
Annual ASCPT Meeting, San Diego, CA, 1995;

- Annual ASCPT Meeting, Orlando, FL, 1996;
Annual ASCPT Meeting, San Diego, CA, 1997;
Annual ASCPT Meeting, New Orleans, LA, 1998.
- 1995 **Invited Lecturer, "Basic Pharmacokinetics"**
Federal Pharmacist's Continuing Education Program, McGuire VA Hospital, Richmond, VA, October 10, 1995 (invited by _____).
- 1996 **Guest Reviewer, *Journal of Pharmacology and Experimental Therapeutics*** (invited by _____ editor).
- 1997 **Workshop Organizer and Instructor, Workshop for Pharmacokineticists "PK/PD Modeling Using ScientistSM"**
Department of Pharmacokinetics and Drug Metabolism, Parke-Davis, April 23, 1997 (invited by _____ Ph.D.).
- 1997 **Member, Internal Advisory Board, NODA Center Grant on the PK/PD of LAAM in Pregnant Women**
Division of Substance Abuse Medicine, MCV/VCU (invited by _____).
- 1997-present **Guest Reviewer, *International Journal of Clinical Pharmacology and Therapeutics*** (invited by Ph.D., editor).
- 1997 **Workshop Organizer and Instructor, "Basic Pharmacokinetics and Pharmacodynamics" and "Phase I Clinical Drug Development"**, Dept. of Pharmacology, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil, July 14-19, 1997 (invited by _____ Ph.D.).
- 1997 **Workshop Organizer and Instructor, Faculty Workshop "PK/PD Modeling Using ScientistSM"**
Department of Pharmacy and Pharmaceutics, MCV/VCU, July 29-31, 1997.
- 1997 **Workshop Organizer and Instructor, Short Course for Clinical Scientists "Basic Pharmacokinetics"**
Allos Therapeutics Inc., Denver, CO, August 3-4, 1997 (invited by _____).
- 1997 **(Outside Consulting) Biopharmaceutics Reviewer, NDA (20-845), DPE I, OCPB, CDER, FDA,**
Rockville, MD (invited by _____).
- 1998-present **Workshop Organizer and Instructor, Workshop for Reviewers on "PK/PD Modeling Using ScientistSM"**
Office of Clinical Pharmacology and Biopharmaceutics, CDER, FDA,
1. January-August, 1998,
2. January - September, 1999 (invited by _____)
<http://views.vcu.edu/wcb/schools/PHA/pha/jvenitz/10/index.html>
- 1998-1999 **Member, PPDM Abstract Screening Committee, AAPS**
1998 Annual Meeting, November 18-22, 1998, San Francisco, CA.
1999 Annual Meeting, November 14-20, 1999, New Orleans, LA.
- 1998-present **Member, Extramural Advisory Board, Nutrition and Therapeutics Integrated Product Team (NTIPT),**
Space Medical Monitoring and Countermeasures Program (SMMaC), Johnson Space Center (JSC),
NASA, Houston, TX, (invited by _____)
(Board Meeting on September 17 and 18, 1998 in Houston, TX).
- 1999 **Workshop Organizer and Instructor, Invited Graduate Student Session "PK/PD Concepts Using Computer Spreadsheets"**
AAPS-South Regional Discussion Group Meeting, Northeastern Louisiana University, Monroe, LA, May 20, 1999 (invited by _____).


SCIENTIFIC CONSULTING ACTIVITIES

- 1988-1989 **Scientific Consultant, (Nonclinical Pharmacokinetics and Toxicokinetics)** Union Carbide, Bushy Run Research Center, Export, PA
- 1989-1990 **Scientific Consultant, (PK/PD Modeling)** Dept. of Clinical Pharmacology, Berlex Laboratories Inc., Wayne, NJ
- 1991-1995 **Scientific Consultant, (Clinical Pharmacology)** BioClin Inc., Richmond, VA

Curriculum Vitae, Jürgen Venitz, M.D., Ph.D.
August 6, 1999

- 1992-1993 **Scientific Consultant, (Clinical Pharmacokinetics/Pharmacodynamics of a Class III Antiarrhythmic Agent),** Norwich Eaton Pharmaceuticals, Inc./Proctor and Gamble, Norwich, NY ()
- 1993 **Scientific Consultant, (PK Modeling)** Dept. of Clinical Pharmacology
Central Research Division, Pfizer Inc, Groton, CT 06340
- 1993-present
1995-present **Scientific Consultant, (Clinical Pharmacology, PK/PD Modeling of Allosteric Hemoglobin Modifiers)**
Member, Scientific Advisory Board,
Allos Therapeutics Inc. (formerly Hemotech Sciences) Inc., Denver, CO ()
- 1994-present **Scientific Consultant (Pharmacokinetics),** Massey-Cancer Center, MCV/VCU
- 1996-present **Scientific Expert Consultant, (Clinical Pharmacology and Pharmacokinetics/ Pharmacodynamics)** Office
of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and
Drug Administration, Rockville, MD,
- 1996-present **Scientific Consultant (Pharmacokinetic Modeling of Oligonucleotide Drugs in Animals and Humans),**
Hybridon, Inc., Worcester,
- 1996-1997 **Scientific Consultant (Pharmacodynamic Modeling of the Bronchoprotective Effects of Albuterol),** Kos
Pharmaceuticals, Miami, FL
- 1997 **Scientific Consultant (PK/PD Modeling),** Pharmacokinetics and Drug Metabolism, Parke-Davis Co., Ann
Arbor, MI ()
- 1998 **Scientific Consultant (Clinical Pharmacology),** Pharmacokinetics and Drug Metabolism, Otsuka America
Pharmaceutical Inc. Rockville, MD ()
- 1998-present **Scientific Consultant (PK/PD Analysis),** Clinical Development Associates, Richmond, VA

REFERENCES



PRESENT ADDRESS

Department of Pharmaceutics, School of Pharmacy
Medical College of Virginia of Virginia Commonwealth University
Box 980533, MCV Station

Curriculum Vitae, Jürgen Venitz, M.D., Ph.D.
August 6, 1999

Room 340, R.B. Smith Building
410 N 12th Street
Richmond, VA 23298-0533
Telephone: _____
Fax: _____
E-mail: _____
Home page: _____

Telephone: _____
Fax: _____
E-mail: _____

APPEARS THIS WAY
ON ORIGINAL

PUBLICATIONS

1. Albrecht, H., Lückner, P.W., Venitz, J. Ein neues Modell zur objektiven Messung und Quantifizierung des Effektes antiinflammatorisch wirksamer Topika [A New Model for Objective Measurement and Quantification of the Effects of Topical Anti-Inflammatory Agents]. *Arzneimittelforschung* 33 (6), 900-901 (1983).
2. Kärner, H., Venitz, J., Lückner, P.W. Correlations Between Transmural Gastric Potential Difference and a Well-Known Mathematical Model. *Methods Find Exp Clin Pharmacol* 6(10), 619-624 (1984).
3. Venitz, J., Lückner, P.W., Niehaus, H. Wirksamkeit einer Dexamethason-Dimetindenmaleat Kombination (Fenistil Plus[®]) bei dermatologischen Erkrankungen unter Berücksichtigung des Plasmacortisolspiegels [Effect of a Betamethasone-Dimethindene-Maleate Combination on Skin Diseases. Determination of Plasma Cortisol Levels before, during and after several Days' Therapy]. *Fortschr Med*, 102 (35), 882-884 (1984).
4. Venitz, J., Lückner, P.W., Albrecht, H., Mailland, F. Measuring the Inhibition of TRH-stimulated Prolactin Secretion by Dihydroergocristine (DEC) in Man: An Indirect Assessment of Bioavailability. *Methods Find Exp Clin Pharmacol* 6 (10), 645-647 (1984).
5. Lückner, P.W., Venitz, J. Magenirritationen von Neobiphyllin - eine Magenpotentialdifferenzanalyse [Gastric Irritations by Neobiphylline - a Gastric Potential Difference Analysis]. *Dustri-Verlag, Dr. Karl Feistle, München-Deisenhofen* 240-251 (1984).
6. Venitz, J., Lückner, P.W. Impedance Cardiography - A Reliable Method for Measuring Cardiac Function Non-Invasively. *Methods Find Exp Clin Pharmacol*. 6(6), 339-346 (1984)
7. Lückner, P.W., Venitz, J. Pupillometrie [Pupillometry]. *Apotheken-Magazin* 2 (4), 144-147 (1984).
8. Venitz, J., Lückner, P.W., Procaccini, R., Vance, J. Extent and Duration of the Protective Effect of Maalox(R) Against Alcohol Challenge: A Transmural Gastric Potential Difference Analysis. *J. Clin. Pharmacol.* (1984).
9. Lückner, P.W., Venitz, J. Die gastrisch transmurale Potentialdifferenz [The Gastric Transmural Potential Difference]. *Apotheken-Magazin* 2 (5), 192-196 (1984).
10. Lückner, P.W., Venitz, J. Die Impedanzkardiographie, ein nichtinvasives Verfahren zur Messung der Herzdynamik [The Impedance Cardiography, a Non-Invasive Procedure to Measure Cardiac Performance]. *Apotheken-Magazin* 2 (7), 284-288 (1984).
11. Lückner, P.W., Venitz, J. Ein nichtinvasives Verfahren zum Wirkungsnachweis von anti-inflammatorischen Substanzen an der Haut [A Non-Invasive Procedure to Determine Topical Effects of Anti-Inflammatory Agents]. *Apotheken-Magazin* 2 (9), 364-368 (1984).
12. Lückner, P.W., Venitz, J. Ein nichtinvasives Verfahren zum Nachweis der Wirkung von β -Rezeptor-Antagonisten [A Non-Invasive Procedure to Determine Effects of β -Adrenergic Antagonists]. *Apotheken-Magazin* 2 (11), 460-463 (1984).
13. Albrecht, H., Alcorn, G., Lückner, P.W., Venitz, J., Rehn, D., Hennings, G. Zur antiinflammatorischen Wirksamkeit einer Kombination aus Dimetindenmaleat und Betamethason in topischen Darreichungsformen [The Anti-Inflammatory Effect of a Combination of Dimethindene Maleate and Betamethasone in Topical Formulations]. *Arzneimittelforschung* 35 (2), 539-542 (1985).
14. Lückner, P.W., Venitz, J. Systolische Zeitintervalle: Indikatoren zur nicht-invasiven Messung der Herzdynamik [Systolic Time Intervals: Non-Invasive Indicators of Cardiac Performance]. *Apotheken-Magazin*, 3 (2), 48-52 (1985).
15. Lückner, P.W., Venitz, J. Die psychometrische Messbatterie, ein Verfahren zur Auslotung von sedativen, stimulierenden oder hypnotischen Effekten [Psychometric Testing, Assessment of Sedative, Stimulating or Hypnotic Effects]. *Apotheken-Magazin*, 3 (3), 96-102 (1985).
16. Lückner, P.W., Venitz, J., Trunz, R. Reizwirkung zweier Antirheumatika an der Magenschleimhaut; eine Potentialdifferenzanalyse von Indometacin im Vergleich zu Proglumetacin, einer neuen nicht-steroidalen antirheumatisch wirksamen Substanz [Gastric Irritations of Two NSAIDs. A Potential Difference Analysis of Indomethacin compared to Proglumetacin, a New NSAID]. *Therapiewoche*, 35 (11) 1178-1185 (1985).

17. Lückner, P.W., Venitz, J., Hey, B., Baykal, M., Hanisch, M., Ritter, W. *Pharmacodynamic and Pharmacokinetic Correlation of Muzolimine with and without Aluminum-hydroxide*. Third International Edrul(R) Symposium, Paris/France, Nov. 29 -Dec. 1, 1984.
Z Kardiol 74 (2 suppl), 141-144 (1985).
18. Ritter, W., Hanisch, M., Lückner, P.W., Venitz, J., Hey, B., Baykal, N. *Pharmacokinetics of Muzolimine After Oral Administration with and without Aluminum-hydroxide in Healthy Volunteers*. Third International Edrul(R) Symposium, Paris/France, Nov. 29 - Dec. 1, 1984.
Z Kardiol 74 (2 suppl), 149-151 (1985).
19. Lückner, P.W., Venitz, J., Adolph, S., Hey, B. *Measurement of the Effect of Cardiovascular Drugs by Impedance Cardiography in Healthy Subjects*.
Methods Find Exp Clin Pharmacol 8 (7), 443-448 (1986).
20. Lückner, P.W., Venitz, J., Ahrens, S., Hey, B. *Gastric Irritation of Oxaprozine, a New Nonsteroidal Anti-Inflammatory Drug in Comparison to Aspirin and Indomethacin: A Gastric Potential Difference Analysis*.
Methods Find Exp Clin Pharmacol 9(7), 469-475 (1987).
21. Shyu, W.C., Shah, V.R., Campbell, D.A., Venitz, J., Jagannathan, V., Pittman, K.A., Barbhaiya, R.H. *Excretion of Cefprozil into Human Breast Milk*.
Antimicrobial Agents Chemotherapy 36(5), 938-941 (1992).
22. Venitz, J. *Rational Clinical Testing of Aerosol Drugs*.
J Biopharm Sci 3(1/2), 131-137 (1992).
23. Jones, L.A., Gonzales, E.R., Venitz, J., Edinboro, L.E., Poklis, A. *Evaluation of the Vision(R) Theophylline Assays in the Emergency Department Setting*.
Ann Emerg Med 21(7), 777-781 (1992).
24. Jones, L.A., Gonzales, E.R., Reines, D.H., Venitz, J. *Assessment of 24-Hour Gastric pH Measurements in Trauma Patients Receiving Intravenous Famotidine*.
Ann Pharmacotherapy 28 (7/8): 841-844 (1992).
25. Garrett, E.R., Venitz, J., Eberst, K., Cerda, J.J. *Pharmacokinetics and Bioavailabilities of Hymecromone in Human Volunteers*.
Biopharm Drug Dispos 14: 13-39 (1993).
26. Polk, R.E., Israel, D., Wang, J., Venitz, J., Miller, J., Stotka, J. *Vancomycin Skin Tests and Prediction of "Red Man Syndrome" in Healthy Volunteers*.
Antimicrob Agents Chemotherapy 37: 2139-2143 (1993).
27. Garnett, W.R., Venitz, J., Wilkens, R., Dimenna, G. *Pharmacokinetic Effects of Fluvastatin in Patients Chronically Receiving Digoxin*.
Am J Med 96 (6A): 84S-86S (1994).
28. Garrett, E.R., Venitz, J. *Comparisons of Detections, Stabilities, and Kinetics of Degradation of Hymecromone and its Glucuronide and Sulfate Metabolites*.
J Pharm Sci 83 (1); 115-6 (1994).
29. Castor, G., Altmayer, P., Venitz, J. *Einfluß der Infusionsdauer auf das Eliminationsverhalten von Alfentanil [Influence of the Infusion Duration on the Elimination of Alfentanil]*.
Anesthesiol Reanimat 20 (4): 97-100 (1995).
30. Gillum, J.G., Johnson, M., Lavole, S., Venitz, J. *Flucytosine Dosing in an Obese Patient with Extrameningeal Cryptococcal Infection*.
Pharmacotherapy 15(2): 251-253 (1995).
31. Jagannathan, V., March, C., Venitz, J. *Determination of Unbound L-Tryptophan in Human Plasma Using High Performance Liquid Chromatography with Fluorescence Detection*.
J Biomed Chromat 9: 305-308 (1995).
32. Slattum, P.W., Venitz, J., Barr, W.H. *Comparison of Methods for the Assessment of Central Nervous System Stimulant Response after Dextroamphetamine Administration to Healthy Male Volunteers*.
J Clin Pharmacol 36: 1039-1050 (1996).
33. Vincent, J., Venitz, J., Teng, R., Barris, B.A., Willavize, S.A., Polzer, R.J., Friedman, H.L. *Pharmacokinetics and Safety of Trovafloxacin in Healthy Male Volunteers Following Administration of Single Intravenous Doses of the Prodrug, Alatrofloxacin*.
J Antimicrob Chemother 39 B: 75-80 (1997).

34. Jagannathan, V., Venitz, J. Pharmacokinetics and CNS Pharmacodynamics of the 5-HT_{1A}-Agonist, Buspirone, in Humans Following Acute L-Tryptophan Depletion Challenge.
Meth Find Exptl Clin Pharmacol 19(5):351-362 (1997).
35. Kovelesky, R.A., Byron, P.R., Venitz, J. Peptidoleukotriene Release and Absorption from the Airways of the Isolated Perfused Guinea Pig Lung Following Chemical and Antigenic Challenge
Pharm Res 16(2): 321-326 (1999).
36. Sathe, P., Venitz, J., Lesko, L. Evaluation of Truncated Areas and C_{max} in the Assessment of Bioequivalence of Long-Half-Life Drugs for Immediate Release Formulations with Different In-Vitro Dissolution Rates.
Pharm Res 16(6): 339-943 (1999).
37. Hermening A., Venitz, J. Development and Validation of A HPLC Assay for RSR13 and its Acyl-Glucuronide in Preclinical and Clinical Biological Samples.
Submitted, *J Pharmaceut Biomed Chromat* (1999).
38. Yuan, R., Venitz, J. Effect of Chronic Renal Failure on the Disposition of a Highly Hepatically Metabolized Drug
In preparation (1999).
39. Ramchandani, V.A., Venitz, J. Pharmacokinetic/Pharmacodynamic Relationship for Intravenous Ethanol in Healthy Young Subjects: Effect of Input-Rate and Degree of Exposure on Subjective and Objective Measures of Impairment
Submitted, *Clin Pharmacol Ther* (1999)
40. Grillo, J.A., Venitz, J., Gonzales, E.R., Ornato, J.P. Prediction of Lidocaine Tissue Concentrations Following Different Dosing Regimens During Cardiac Arrest Using a Physiologically Based Pharmacokinetic Model.
In preparation, *Crit Care* (1999).
41. Li, C.C., Venitz, J. Development and Validation of a Mathematical Model for Bacterial Time-Kill Curves and Postantibiotic Effect of Ampicillin, Tobramycin and Ciprofloxacin against *Escherichia Coli* ATCC 25922 In-Vitro.
In preparation, *J Pharmacokin Biopharm* (1999).
42. Welty, D., Soine, W., Nestler, J., Venitz, J., Wood, J. The Effect of Serum Glucose and Insulin on the Metabolic Disposition of Amobarbital in Humans.
In preparation, *Meth Find Exptl Clin Pharmacol* (1999).

BOOK CHAPTERS

1. Venitz, J. Pharmacokinetic-Pharmacodynamic Modeling of Reversible Drug Effects, Chapter 1
in Derendorf H. and Hochhaus G. (eds.), "Handbook on Pharmacokinetic-Pharmacodynamic Correlations" (ISBN 0-8493-8303-X),
CRC-Press, Boca Raton, FL (1994).
2. Venitz, J. Prerequisites, Objectives and Clinical Trial Designs of a Phase I Program, in "Pharmacokinetic/Pharmacodynamic Analysis II - Accelerating Drug Discovery and Analysis" (ISBN 1-57936-045-9),
International Business Communications, Southborough, MA (1997).

ORAL PRESENTATIONS/ABSTRACTS

1. Venitz, J., Schwarz, W. Blockade von Na-strömen in Froschmuskelfasern durch Lokalanästhetika [Block of Sodium Currents in Frog Muscle Fibers by Local Anesthetics]
Selected Podium Presentation, Spring Meeting of the Deutsche Physiologische Gesellschaft in Kiel, West Germany, April 15, 1980.
Pflügers Arch Suppl R-8 (1980).
2. Venitz, J. Nachteile und Fehler bei der Interpretation pupillometrischer Ergebnisse [Pitfalls and Errors in Interpreting Pharmacodynamic Results of Pupillometric Measurements]
Invited Speaker, Meeting of the Scientific Advisory Board, Institut für Klinische Pharmakologie Bobenheim, West Germany, April 19, 1983.
3. Kärner, H., Venitz, J., Lückner, P.W. Correlations between the Transmural Gastric Potential Difference and a Well Known Mathematical Model
Invited Speaker, 7. Bobenheimer Allerheiligengespräch [Clinical Research Conference], Bobenheim, West Germany, November 2, 1983.

4. Venitz, J. *Systolische Zeitintervalle und Impedanzkardiographie [Use of Systolic Time Intervals and Impedance Cardiography to Assess Cardiac Function in Patients]*
Invited Guest Speaker, Department of Anesthesiology Seminar, Universitätsklinik Homburg, Universität des Saarlandes, Homburg, West Germany, March 7, 1984.
5. Venitz, J. *The Impedance Cardiography and Systolic Time Intervals as a Tool for Measuring Cardiac Function*
Invited Speaker, European Symposium on Recent Aspects in Drug Development and Clinical Pharmacology, Paris, France, June 5-6, 1984.
6. Venitz, J., Baykal, N., Trunz, R. *Impedance Cardiography: A Non-Invasive Technique of Measuring Cardiac Function in Man*
Invited Speaker, International Minisymposium on Clinical Pharmacology, Barcelona, Spain, October 8-9, 1984.
7. Venitz, J., Lückner, P.W. *Impedance Cardiography - A Tool of Measuring Cardiac Function*
Invited Speaker, 8. Bobenheimer Allerheiligengespräch [Clinical Research Conference], Grünstadt, West Germany, November 1, 1984.
8. Venitz, J. *Physiologische Korrelate des Schmerzes [Physiological Correlates of Pain]*
Invited Guest Speaker, Scientific Advisory Board Meeting, Institut für Klinische Pharmakologie, Grünstadt, West Germany, April 27, 1985.
9. Venitz, J., Lückner, P.W. *The Impedance Cardiography - A Non-Invasive Technique for the Determination of Hemodynamic Parameters in Clinical Pharmacology*
Invited Speaker, Clinical-Pharmacological Symposium I, Titisee/Black Forest, West Germany, May 10-11, 1985.
10. Venitz, J., Lückner, P.W. *Evaluation of Pharmacodynamic Data in Phase I Studies Concerning Efficacy and Side Effects*
Invited Speaker, Seminaires A.R.C., Cases pharmacodynamiques et pharmacocinétiques de l'essai clinique des médicaments, Paris, France, June 25-26, 1985.
11. Venitz, J. *Non-invasive Techniques to Measure Pharmacodynamic Responses in Clinical Pharmacology*
Guest Speaker, College of Pharmacy Seminar, University of Florida, Gainesville, FL, February 26, 1986 (invited by E.R. Garrett, Ph.D.).
12. Venitz, J., Garrett, E.R. *Pharmacokinetics of 4-Methyl-Umbelliferone in Humans*
Guest Speaker, College of Pharmacy Seminar, University of Florida, Gainesville, FL, November 25, 1987 (invited by E.R. Garrett, Ph.D.).
13. Venitz, J., Garrett, E.R., Cerda, J.J. *Pharmacokinetics and Pharmacodynamics of a New Antispasmodic and Choleric Drug, Hymecromone, in Man*
Invited Guest Speaker, Gastroenterology Research Conference, College of Medicine, University of Florida, Gainesville, FL, November 29, 1987 (invited by J. Cerda, MD).
13. Venitz, J. *Principles of Pharmacokinetics*
Invited Guest Speaker, Union Carbide Research Seminar, Bushy Run Research Center, Export, PA, March 3, 1988 (invited by S. Frantz, Ph.D.).
14. Venitz, J. *Use of Spreadsheet Programs for Pharmacokinetic-Pharmacodynamic Modeling*
Invited Guest Speaker, Department of Bioengineering Seminar, Medical College of Virginia, Richmond, VA, May 17, 1989 (invited by D. Mikulecky, Ph.D.).
15. Venitz, J. *Introduction in Pharmacokinetic-Pharmacodynamic Modeling*
Invited Guest Speaker, Clinical Pharmacology Seminar, Berlex Laboratories, Wayne, NJ, October 16, 1989 (invited by P. Hinderling, MD).
16. Venitz, J. *Pharmacokinetic-Pharmacodynamic Simulations*
Invited Guest Speaker, College of Pharmacy Seminar, University of Florida, Gainesville, FL, May 4, 1990 (invited by H. Derendorf, Ph.D.).
17. Venitz, J. *Use of Physiological Modeling to Explain Variability in Drug Disposition*
Invited Speaker, 5th Annual AAPS Meeting, Las Vegas, NV, November 5-8, 1990 (invited by W. R. Garrett, Pharm.D.).
18. Venitz, J. *Pharmakokinetische-Pharmakodynamische Modelle [Pharmacokinetic-Pharmacodynamic Models]*
Invited Guest Speaker, Department of Pharmacy Seminar, Eidgenössische Technische Hochschule, Zürich, Switzerland, January 8, 1991 (invited by P. Langguth, Ph.D.).
19. Venitz, J. *Pharmacodynamic Concepts in Drug Evaluation and Development*
Invited Speaker, 1st Annual Southeastern Regional AAPS Meeting, Charleston, SC, April 4-5, 1991 (invited by H. Derendorf, Ph.D.).

20. **Venitz, J.** *Non-Invasive Methods to Assess Cardiovascular Function and Their Application in Pharmacodynamics*
Invited Speaker, Annual Eastern Regional AAPS Meeting, New Brunswick, NJ, June 6-7, 1991 (invited by K. Thakker, Ph.D.).
21. **Venitz, J.** *Clinical Testing of Aerosols*
Invited Speaker, Conference on Regulatory Issues in Aerosol Drug Development, Arlington, VA, June 12-14, 1991 (invited by P. Byron, Ph.D.).
22. **Venitz, J.** *Pharmacodynamics - Basic Concepts and Applications*
Invited Guest Speaker, Graduate Research Seminar, St. John's University College of Pharmacy and Allied Health Professions, Jamaica, NY, October 17, 1991 (invited by I. Reddy, Ph.D.).
23. **Venitz, J., Walton, T., Healy, D., Polk, R.** *Use of Pharmacodynamic Modeling to Describe Drug-Induced Histamine Release with Vancomycin as a Model Compound*
Selected for PPDM Podium Presentation, 6th Annual AAPS Meeting, Washington, DC, November 14-16, 1991.
Pharm Res 8(10), S-274, October 1991 Supplement.
24. **Venitz, J.** *Pharmacodynamic Concepts and Their Application in Phase I Studies*
Invited Guest Speaker, Hudson Valley Pharmaceuticals Discussion Group, Clifton NJ, April 24, 1992 (invited by H. Lau, Ph.D.).
25. **Venitz, J.** *Rational Clinical Testing of Aerosol Drugs*
Invited Speaker, Respiratory Drug Delivery III Symposium, Williamsburg, VA, May 17-22, 1992 (invited by P. Byron, Ph.D.);
J Biopharm Sci 3(1/2), 131-137 (1992).
26. **Venitz, J.** *Introduction into Pharmacokinetic/Pharmacodynamic Modeling Using Computer Spreadsheet Simulations*
Invited Guest Speaker, Biopharmaceutics Scientific Rounds, Division of Biopharmaceutics, Food and Drug Administration, Rockville, MD, November 4, 1992 (invited by H. Malinowski, Ph.D.).
27. **Venitz, J.** *Monte Carlo Simulations in Population Pharmacokinetics Using Computer Spreadsheets*
Invited Guest Speaker, Biopharmaceutics Scientific Rounds, Division of Biopharmaceutics, Food and Drug Administration, Rockville, MD, April 14, 1993 (invited by T. Ludden, Ph.D.).
28. **Venitz, J.** *Effect of Input Rate on Pharmacodynamics: Clinical Implications for Immediate versus Controlled Release Dosage Forms*
Invited Speaker, Annual Eastern Regional AAPS Meeting, New Brunswick, NJ, June 7-8, 1993 (invited by K. Thakker, Ph.D.).
29. **Venitz, J.** *Monte Carlo Simulations in Population Pharmacokinetics Using Computer Spreadsheets*
Invited Guest Speaker, Clinical Research Seminar, Central Research Division, Pfizer Inc, Groton, CT, June 28, 1993 (invited by H. Friedman, MD).
30. **Venitz, J.** *Effect of Changes in Input Rate on Pharmacokinetics and Pharmacodynamics: Theoretical and Clinical Implications for Immediate Versus Controlled Release Dosage Forms*
Invited Guest Speaker, Research Seminar, Division of Bioequivalence, Food and Drug Administration, Rockville, MD, March 10, 1994 (invited by P. Sathe, Ph.D.).
31. **Venitz, J.** *Clinical Assessment of the Pharmacokinetic/Pharmacodynamic Performance of Oral Controlled Release Dosage Forms*
Invited Speaker, 36th Annual Pharmacy Congress, St. John's University College of Pharmacy and Health Professions, Garden City, New York, May 4, 1994 (invited by I. Reddy, Ph.D.).
32. **Venitz, J., Ramchandani, V.R., Comstock, T.C.** *Use of Spreadsheets to Teach Pharmacokinetic and Pharmacodynamic Concepts to Pharmacy Students*
Presenter, Technology '94, Virginia Commonwealth University, Richmond, VA, May 4, 1994.
33. **Venitz, J.** *Preclinical Pharmacokinetics and Pharmacodynamics of RSR-13 - Preliminary Results*
Invited Speaker, Scientific Symposium on Hemoglobin Allosteric Modifiers: Physics to Physicians, Allos Therapeutics Inc., Washington, DC, April 18, 1995 (invited by S. Hoffman, MD, Ph.D.).
34. **Venitz, J.** *Pharmacokinetic/Pharmacodynamic Profiling of a Novel Pharmacologic Agent - Preclinical and Clinical Pharmacology of an Allosteric Modifier of Hemoglobin*
Invited Guest Speaker, Research Seminars in Drug Development, Department of Pharmacy and Pharmaceutics, MVCVCU, November 21, 1995 (invited by S. Wu-Pong, Ph.D.).
35. **Venitz, J.** *From the Animal to the Human: Pharmacokinetic-Pharmacodynamic Modeling of the Effects of an Allosteric Modifier of Hemoglobin*
Invited Guest Speaker, Division of Pharmaceutics Seminar, School of Pharmacy, University of North Carolina, Chapel Hill, NC, April 4, 1996 (invited by A. J. Hickey, Ph.D.).

36. Venitz, J. *In-Vitro Human Plasma Protein and RBC Binding of Allosteric Modifiers of Hemoglobin - Potential Significance for Drug Discovery and Development - A Progress Report*
Invited Speaker, Scientific Symposium on Allosteric Effectors of Hemoglobin, Allos Therapeutic Inc., Washington, DC, April 30, 1996 (invited by M. Gerber, MD).
37. Venitz, J. *Pharmacokinetic-Pharmacodynamic Modeling of the Effects of an Allosteric Modifier of Hemoglobin in Humans - Assessment of Plasma Protein Binding and Red Blood Cell Partitioning Ex-Vivo*
Invited Guest Speaker, Research Seminar, Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, May 24, 1996 (invited by L. Lesko, Ph.D.).
38. Venitz, J. *Clinical Pharmacology of Escalating IV Infusions of RSR13 in Healthy Young Volunteers - Validation of Clinically Useful Markers of the Pharmacological Effects of Allosteric Modifiers of Hemoglobin*
Invited Speaker, Scientific Symposium on Hemoglobin Allosteric Modifiers: Nonclinical Meeting, Allos Therapeutics Inc., Chicago, IL, June 7, 1996 (Invited by M. Gerber, MD).
39. Venitz, J. *Pharmakologische Reduzierung der Sauerstoffaffinität des Hämoglobinmoleküls: Klinisch-Pharmakologische Studien mit RSR13, einem neuen allosterischen Hämoglobin-Modifizierer* [Pharmacological Reduction of the Oxygen Affinity of the Hemoglobin Molecule: Clinical Pharmacology of RSR13, a Novel Allosteric Hemoglobin Modifier]
Invited Guest Speaker, Einführende Vorlesung zum Kurs der Speziellen Pharmakologie [Medical Pharmacology Lecture], Department of Pharmacology and Toxicology, School of Medicine, Universität des Saarlandes, Homburg/Saar, Germany, June 20, 1996 (invited by H. J. Haas, Ph.D.).
40. Venitz, J. *Prerequisites, Objectives and Clinical Trial Designs of a Phase I Program - Trials and Tribulations with Investigational Drugs*
Invited Guest Speaker, Research Seminar, Hybridon Inc., Worcester, MA, December 6, 1996 (invited by B. Dvorchik, Ph.D.).
41. Venitz, J. *Prerequisites, Objectives and Clinical Trial Designs of a Phase I Program - Trials and Tribulations with Investigational Drugs*
Invited Guest Speaker, Clinical Pharmacology Seminar, Parke-Davis, Ann Arbor, MI, December 10, 1996 (invited by E. Posvar, MD, MPH).
42. Venitz, J. *Prerequisites, Objectives and Clinical Trial Designs of a Phase I Program*
Invited Speaker, Pharmacokinetics/Pharmacodynamics Conference, International Business Communications, Washington, DC, December 12-13, 1996 (invited by W. Colburn, Ph.D.).
43. Venitz, J. *Critical Issues in the Measurement of Pharmacological Effects of CNS Agents in Clinical Trials: Assessing the PK/PD Relationship in Clinical Pharmacological Paradigms.*
Invited Speaker, Johnson Space Center, NASA, Houston, TX, March 26, 1997 (invited by L. Putcha, Pharm.D.).
44. Venitz, J. *PK/PD Modeling of the Effects of a Novel Allosteric Modifier in Humans - Assessment of Plasma Protein Binding and Red Blood Cell Binding Ex-Vivo*
Invited Guest Speaker, Pharmacokinetics/Drug Metabolism Research Seminar, Parke-Davis, Ann Arbor, MI, April 23, 1997 (invited by R. Powell, Pharm.D.).
45. Venitz, J. *Clinical Pharmacology of a Novel Allosteric Hemoglobin Modifier*
Invited Speaker, New Developments in Clinical Pharmacy and Clinical Pharmacology Symposium, Institut für Pharmazeutische Chemie, Universität Münster, Münster Germany, May 24, 1997 (invited by H. Derendorf, Ph.D.).
46. Venitz, J. *PK/PD Modeling of Tolerance for CNS-Active Drugs*
Invited Speaker, Annual Southeastern Regional AAPS Meeting, Morrisville/Research Triangle Park, NC, June 23, 1997 (invited by J. Hui, Ph.D.).
47. Venitz, J. *Update on the Clinical Pharmacology of the Allosteric Hemoglobin Modifier, RSR13*
Invited Speaker, Allos Pharmaceuticals Inc., Denver, CO, August 3, 1997 (invited by M. Gerber, MD).
48. Venitz, J. *Testing New Drugs in Early Clinical Development: Allosteric Modifiers of Hemoglobin, a New Approach in Pharmacotherapy, Hit the Clinic*
Invited Guest Speaker, Pharmacotherapy Grand Rounds, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, September 29, 1997 (Invited by T. Comstock, Pharm.D.).
49. Venitz, J., Ramchandani, V., Slattum, P.W. *Pharmacokinetic/Pharmacodynamic Modeling of Tolerance to Ethanol: Effects of Gender and Age*
Invited Speaker (presented by Dr. P.W. Slattum due to a family emergency), Symposium on Drug Abuse and Pharmacokinetics, 99th Annual Meeting, ASCPT, New Orleans, LA, March 30, 1998 (invited by J. M. Perel, Ph.D.).
50. Venitz, J. *Clinical Pharmacology of Allosteric Hemoglobin Modifiers*
Invited Guest Speaker, Division of Clinical Pharmacology Seminar, Uniformed Services University of the Health Sciences (U.S.U.H.S.), Bethesda, MD, April 9, 1998 (invited by T. Pawlova, MD).

51. Venitz, J. *Pharmacokinetic-Pharmacodynamic Modeling of Tolerance for CNS-Active Agents*
Invited Speaker, Office of Clinical Pharmacology and Biopharmaceutics (OCPB), CDER, FDA, Rockville, MD, September 24, 1998 (invited by L. Lesko Ph.D.).
52. Venitz, J. *Clinical Pharmacology of Synthetic Allosteric Hemoglobin Modifiers: Validation of Clinically Relevant Surrogate Endpoints and Assessment of Plasma Protein Binding and Red Blood Cell Binding Ex-Vivo*
Invited Guest Speaker, Center for Drug Evaluation and Research (CDER), Food and Drug Administration, Rockville, MD, October 7, 1998 (invited by Janet Woodcock, MD).
53. Venitz, J. *Use of Pharmacokinetic-Pharmacodynamic Modeling to Evaluate the Early Clinical Pharmacology of a Novel Synthetic Allosteric Hemoglobin Modifier*
Invited Guest Speaker, Research Seminar in Drug Development, Dept. of Pharmaceutics, MCV/VCU, October 13, 1998 (invited by S. Wu-Pong, Ph.D.).
54. Venitz, J. *Clinical Pharmacology of a Novel Oxygen Booster: Pharmacokinetics and Pharmacodynamics of a Synthetic Allosteric Modifier, RSR13*
Invited Guest Speaker, Research Seminar, Department of Pharmacology and Toxicology, MCV/VCU, November 3, 1998 (invited by G. Kunos, MD, Ph.D.).
55. Venitz, J. *PK/PD Considerations in Renal Impairment Studies: An Academic Perspective*
Invited Speaker, Symposium on PK/PD Considerations in Renal and Hepatic Impairment Studies, ASCPT Clinical Pharmaceutical Development and Regulatory Affairs, 100th Annual ASCPT Meeting, San Antonio, TX, March 18, 1999 (invited by M. Mehta, Ph.D.).
56. Venitz, J. *Pharmakokinetik und Pharmakodynamik eines neuartigen, synthetischen allosterischen Hämoglobin-Modifizierers [PK and PD of a Novel, Synthetic Allosteric Hemoglobin Modifier]*
Invited Guest Speaker, Deutsche Pharmazeutische Gesellschaft, Institut für Pharmazie, Johannes Gutenberg Universität Mainz, Germany, June 2, 1999 (invited by Peter Langguth, Ph.D.).
57. Venitz, J. *Update on the Clinical Pharmacology of a Novel, Synthetic Allosteric Hemoglobin Modifier*
Invited Speaker, New Developments in Clinical Pharmacy and Clinical Pharmacology Symposium, UFR de Pharmacie (School of Pharmacy), Université de Reims Champagne, Reims, France, June 5, 1999 (invited by H. Derendorf, Ph.D. and Matthieu Kaltenbach, Pharm.D., Ph.D.).
58. Venitz, J. *Pharmacokinetic/Pharmacodynamic Modeling in Drug Research: Examples of Success and Failure. How Can Academicians Help?*
Invited Speaker, PK/PD Modeling and Simulation: Key Issues and Unresolved Questions in Drug Development and Regulatory Decision Making Symposium, 28th Annual ACCP (Pharmacology) Meeting, Rockville, MD, September 16, 1999 (invited by H. Derendorf, Ph.D. and L. Lesko, Ph.D.).
59. Venitz, J. *The Role and Importance of Well-Designed Preclinical Pharmacokinetic Studies: Rational Approach to Drug Development in the New Millennium*
Invited Speaker, Pharmacokinetics Symposium, 20th Annual ACT (American College of Toxicology) Meeting, McLean, VA, November 7-10, 1999. (invited by A. Zutshi, Ph.D.).
60. Venitz, J. *Pharmacokinetic/Pharmacodynamic Considerations in Chronic Renal Impairment*
Invited Speaker, Studies in Renal and Hepatic Impairment Symposium, Annual AAPS Meeting, Indianapolis, IN, November XX, 2000. (invited by M. Mehta, Ph.D. and D. Garg, Ph.D.).

POSTER PRESENTATIONS

1. Venitz, J., Barr, W.H. *Influence of Circadian Rhythm on the Pharmacodynamic Response of Two Verapamil Controlled Release (CR) Dosage Forms*
3rd Annual Meeting, Orlando, AAPS, FL, October 30 - November 3, 1988.
Pharm Res 5(10), S-169, October 1988 Supplement.
2. Lathia, C.D., Sica, D.A., Venitz, J., Wood, J.H. *Tubular Transport of Guanfacine: Kinetic Modeling*
91st Annual Meeting, ASCPT, San Francisco, CA, March 21-23, 1990.
Clin Pharmacol Ther 47(2), S-175, February 1990 Supplement.
3. Sica, D.A., Lathia, C.D., Venitz, J., Wood, J.H. *Active Tubular Secretion and Reabsorption of Guanfacine in Man*
91st Annual Meeting, ASCPT, San Francisco, CA, March 21-23, 1990.
Clin Pharmacol Ther 47(2), S-202, February 1990 Supplement.
4. Lathia, C.D., Venitz, J., Sica, D.A., Wood, J.H. *Pharmacodynamics of IV Guanfacine at Three Steady-State Concentrations*

in Normal Volunteers

91st Annual Meeting, ASCPT, San Francisco, CA, March 21-23, 1990.

Clin. Pharmacol. Ther. 47(2), S-202, February 1990 Supplement.

5. Venitz, J., Garnett, W.R., Slattum, P.W., Yong, C.L. Bradycardic Effect of Oxybutynin, an Antimuscarinic Compound, after Oral Administration to Young and Elderly Healthy Volunteers
3rd Symposium Frontiers of Pharmacokinetics and Pharmacodynamics, Baltimore, MD, April 2-4, 1990.
6. Garnett, W.R., Venitz, J., Moherman, L., Stanley, H., Karim, A., Smith, M.E. Evaluation of an Interaction between Misoprostol and Single and Multiple Doses of Diclofenac in the Elderly
19th Annual Meeting, ACCP (Pharmacology), Las Vegas, NV, November 5-8, 1990.
J Clin Pharmacol 30 (9), S-48, September 1990.
7. Garnett, W.R., Venitz, J., Barstow, L., Karim, A., Smith, M.E., Neuhaus, J. Evaluation of a Potential Interaction between Misoprostol and Cyclosporine
5th Annual Meeting, AAPS, Las Vegas, NV, November 5-8, 1990.
Pharm Res 7(9), S-51, September 1990 Supplement.
8. Jones, L.A., Venitz, J., Edinboro, L.E., Gonzales, E.R. Evaluation of VISION Theophylline I Assay in the Emergency Room Setting
92nd Annual Meeting, ASCPT, San Antonio, TX, March 13-15, 1991.
Clin Pharmacol Ther , February 1991 supplement.
9. Jagannathan, V., Venitz, J., Shyu, W.C., Shah, V.R., Pittman, K.A., Wilber, R., Barbhaiya, R.H. Penetration of Cefprozil into Breast Milk
11th Annual GRASP Meeting, Pittsburgh, PA, May 30-June 1, 1991.
10. Slattum, P.W., Venitz, J., Barr, W.H. EEG Response to Fenfluramine in Healthy Subjects: A Pilot Study
11th Annual GRASP Meeting, Pittsburgh, PA, May 30-June 1, 1991.
11. Collier, J., Lau, H., Faleck, H., Cook, T., Venitz, J., Garnett, W.R., Chan, K., John, V., Cheung, W. Plasma Concentrations and Tolerability of CGS-18416A in Healthy Male Subjects after Single Ascending Oral Doses of 80 mg to 2000 mg
Annual Eastern Regional Meeting, AAPS, New Brunswick, NJ, June 6-7, 1991.
12. Jones, L.A., Edinboro, L.E., Venitz, J., Gonzalez, E.R. Evaluation of Vision Theophylline II Assay in the Emergency Setting
Annual Meeting, ACCP (Pharmacy), Minneapolis, MN, August 18-21, 1991.
13. Venitz, J., Garnett, W.R., Wang, J., Karim, A., Neuhaus, J., Moran, S.M., Hyndman, V. Effect of Enisoprost on Cyclosporine Pharmacokinetics in Healthy Male Subjects
6th Annual Meeting, AAPS, Washington, DC, November 14-16, 1991
Pharm Res 8(10), S-63, October 1991 Supplement.
14. Garnett, W.R., Venitz, J., Karim, A., Neuhaus, J., Moran, S.M., Hyndman, V. Effect of Cyclosporine on the Pharmacokinetics of Enisoprost in Healthy Male Subjects
6th Annual Meeting, AAPS, Washington, DC, November 14-16, 1991
Pharm Res 8(10), S-65, October 1991 Supplement.
15. Garnett, W.R., Venitz, J., Wilkens, R., Dimenna, G., Jokubaitis, L.A. Double-Blind Evaluation to Determine the Influence of Fluvastatin Administration on the Pharmacokinetics of Oral Digoxin in a Patient Population Chronically Receiving Digoxin
6th Annual Meeting, AAPS, Washington, DC, November 14-16, 1991
Pharm Res 8(10), S-63, October 1991 Supplement.
16. Slattum, P.W., Venitz, J., Barr, W.H. Evaluation of Quantitative Electroencephalography for Assessment of Central Nervous System Response: Part I. Reproducibility of Control Responses
6th Annual Meeting, AAPS, Washington, DC, November 14-16, 1991
Pharm Res 8(10), S-65, October 1991 Supplement.
17. Jones, A.L., Gonzalez, E.R., Kulzer, S., Reines, H.D., Venitz, J. Comparison of Continuous versus Intermittent Infusion of Famotidine in Critically Injured Patients
21st Annual Educational and Scientific Symposia (SCCM), San Antonio, TX, May 26-28, 1992.
18. Shyu, W.C., Shah, V.R., Venitz, J., Jagannathan, V., Pittman, K.A., Wilber, R., Barbhaiya, R.H. Excretion of Cefprozil into Breastmilk
93rd Annual Meeting, ASCPT, Orlando, FL, March 18-20, 1992
Clin Pharmacol Ther 51(2), S-182, February 1992 supplement.
19. Dile, C., Tendolkar, A.V., Venitz, J., Chinchilli, V., Barr, W.H., Hinderling, P.H., Drug-Drug Interaction between Sematilide HCL (S) and Diltiazem (D)

- 93rd Annual Meeting, ASCPT, Orlando, FL, March 18-20, 1992
Clin Pharmacol Ther 51(2), S-156, February 1992 supplement.
20. **Slattum, P.W., Venitz, J., Barr, W.H.** Pharmacokinetics, Neuroendocrine Response and Mood Following Oral Administration of Dextroamphetamine in Healthy Volunteers
7th Annual Meeting, AAPS, San Antonio, TX, November 16-19, 1992
Pharm Res 9 (10), S-87, October 1992 supplement.
21. **Venitz, J., Li, C.C.** Simulation of *In-Vitro* Bacterial Growth Inhibition Using a Sigmoidal Model Incorporating Area Under the Concentration-Time Profile (AUC) of Antimicrobial Agents
Annual Eastern Regional Meeting, AAPS, New Brunswick, NJ, June 1993.
22. **Slattum, P.W., Venitz, J., Barr, W.H.** Evaluation of Quantitative EEG For Assessment of CNS Stimulant Response
14th Frontiers Symposium, ACCP, Assessing the Pharmacodynamics of CNS Acting Medications, Rockville, MD, April 29-30, 1994.
23. **Ramchandani, V.A., Venitz, J.** Pharmacodynamics of Ethanol in Healthy Male Subjects: Effect of Dose and Dose-Rate on Psychometric Performance and Mood
14th Frontiers Symposium, ACCP, Assessing the Pharmacodynamics of CNS Acting Medications, Rockville, MD, April 29-30, 1994.
24. **Kirkwood, C.K., Fleishaker, J.C., Tollison, S.M., Venitz, J., Elswick, R.K., Sood, R.K.** Comparison of Tolerance to the Psychomotor Effects of Adinazolam and Alprazolam
Annual Meeting, ACCP, Orlando, FL, October 1994.
25. **Sathe, P., Lesko, L., Venitz, J.** Dissolution Sensitivity Analysis of two Long Half-Life Drugs Using a Monte-Carlo Technique
9th Annual Meeting, AAPS, San Diego, CA, November 7-13, 1994.
Pharm Res 11 (9): S- (1994).
26. **Garnett, W.R., Venitz, J., Kroner B., Sahlroot, J.T., Pledger, G.W.** Pharmacokinetics of a Single Dose of Flunarizine in Comedicated Refractory Epileptic Patients
Annual Meeting, American Epilepsy Society, New Orleans, LA, December 6-7, 1994.
Epilepsia 35 (supplement 8): 94 (1994).
27. **Li, C.C., Venitz, J.** Simulation of Bacterial Time-Kill Curves Induced by Antimicrobial Agents *In-Vitro* Using a Sigmoidal Model Incorporating Area Under the Drug Concentration-Time Profile
Annual Meeting, Chinese Association of Pharmaceutical Sciences, Kaojsiung, Taiwan, December 17-18, 1994.
28. **Li, C.C., Venitz, J.** Mathematical Modeling of Time-Kill Curves and Postantibiotic Effect of Ampicillin, Tobramycin and Ciprofloxacin to *Escherichia Coli* ATCC 25922 *In-Vitro*
Annual Meeting, Chinese Association of Pharmaceutical Sciences, Kaojsiung, Taiwan, December 17-18, 1994.
29. **Grillo, J.A., Venitz, J., Gonzalez, E.R.** Prediction of Lidocaine Tissue Concentrations for Different Dosing Regimens During Cardiac Arrest Using a Physiologically Based Pharmacokinetic Model (PBPk)
Annual Meeting, Society of Critical Care Medicine, San Francisco, February 1-5, 1995.
Crit Care Med 23 (1): A180 (1995).
30. **Kirkwood, C.K., Fleishaker J.C., Tollison, S.M., Venitz, J., Elswick, R.K., Sood, R.K.** Comparison of Tolerance to the Psychomotor Effects of Adinazolam and Alprazolam
(Encore Presentation) Annual Winter Practice and Research Forum, ACCP, Orlando, FL, February 12-15, 1995.
31. **Ramchandani, V.A., Venitz, J.** Pharmacokinetic and Pharmacodynamic Relationship for Oral Ethanol: I. Effect of Dose and Input-Rate on Pharmacokinetics
96th Annual Meeting, ASCPT, San Diego, CA, March 15-17, 1995
Clin Pharmacol Ther 57 (2): 216 (1995).
32. **Ramchandani, V.A., Venitz, J.** Pharmacokinetic and Pharmacodynamic Relationship for Oral Ethanol: II. Effect of Dose and Input-Rate on Psychometric Performance and Mood
96th Annual Meeting, ASCPT, San Diego, CA, March 15-17, 1995
Clin Pharmacol Ther 57 (2): 216 (1995).
33. **Venitz, J., Kier, L.** Development of Neural Networks to Correlate Structure and Boiling Points of Chloroalkanes - Assessment of Descriptive Performance
4th Annual Southeast Regional Meeting, AAPS, Durham, NC, June 19, 1995.
34. **Ghosh, R., Venitz, J.** The Isolated Perfused Guinea Pig Lung (IPGPL) Model to characterize Histamine-Induced Bronchoconstriction and the Bronchoprotective Effect of Albuterol
10th Annual Meeting, AAPS, Miami, FL, November 4-9, 1995.

Pharm Res 12 (9): 403 (1995).

35. Jagannathan, V., March, C., Venitz, J. Validation of Acute L-Tryptophan Depletion as a Method to Lower Plasma L-Tryptophan Concentrations in Healthy Male Volunteers
10th Annual Meeting, AAPS, Miami, FL, November 4-9, 1995.
Pharm Res 12 (9): 107 (1995).
36. Jagannathan, V., Venitz, J. Acute CNS Effects of Single Doses of Buspirone in Healthy Males Placed on a L-Tryptophan-Deficient Diet
10th Annual Meeting, AAPS, Miami, FL, November 4-9, 1995.
Pharm Res 12 (9): 106 (1995).
37. Ramchandani, V.A., Venitz, J. Pharmacokinetic Modeling For Oral Ethanol in Healthy Male Subjects: Effect of Dose and Input Rate
10th Annual Meeting, AAPS, Miami, FL, November 4-9, 1995.
Pharm Res 12 (9): 104 (1995).
38. Li, C.C., Venitz, J. Development and Validation of a Mathematical Model of Time-Kill Curves and Postantibiotic Effect of Ampicillin, Tobramycin and Ciprofloxacin to E. Coli ATCC 25922 *In-Vitro*
(Selected for PPDM Podium Presentation) 10th Annual Meeting, AAPS, Miami, FL, November 4-9, 1995.
Pharm Res 12 (9): 371 (1995).
39. Kress, K., Slattum, P.W., Venitz, J. Effects of Restricted Activity and Blood Loss on Orthostatic Vital Signs in Healthy Male Drug Study Subjects
17th Annual Undergraduate Research Seminar, Morgantown, WV, October 16, 1995.
40. Jagannathan, V., Venitz, J. Pharmacokinetics and Pharmacodynamics of Buspirone in a Human Experimental Model of Depression
97th Annual Meeting, ASCPT, Orlando, FL, March 20-22, 1996.
Clin Pharmacol Ther 59 (2): 148 (1996).
41. Slattum, P.W., Briggs, G., Hawley, J., Garnett, W.R., Venitz, J. Effects of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Diphenhydramine
97th Annual Meeting, ASCPT, Orlando, FL, March 20-22, 1996.
Clin Pharmacol Ther 59 (2): 148 (1996).
42. Ramchandani, V.A., Venitz, J. An Experimental Model for the Investigation of Acute Tolerance to Ethanol: Assessment of Pharmacokinetic Variability
97th Annual Meeting, ASCPT, Orlando, FL, March 20-22, 1996.
Clin Pharmacol Ther 59 (2): 148 (1996).
43. Ramchandani, V.A., Venitz, J. Psychometric Performance and Subject-Rated Impairment Following Intravenous Ethanol Infusions in an Experimental Model of Acute Tolerance
Joint Scientific Meeting, Research Society on Alcoholism and International Society for Biomedical Research on Alcoholism, Washington, D.C., June 22-27, 1996
Alcohol Clin Exp Res 20: 108A (1996).
44. Ghosh, R., Venitz, J. *In-Vivo* Tolerance Development to the Bronchoprotective Ability of Albuterol Against *In-Vitro* Histamine Challenges in Guinea Pig Lungs
10th Annual Eastern Regional AAPS Meeting, June 13-14, 1996, New Brunswick, NJ.
45. Ramchandani, V.A., Venitz, J. A Two-Compartment Pharmacokinetic Model for Intravenous Ethanol and Healthy Male and Female Subjects
Annual Eastern Regional AAPS Meeting, June 13-14, 1996, New Brunswick, NJ.
46. Venitz, J., Gerber, M., Abraham, D. Pharmacological Effects of Escalating IV Doses of an Allosteric Hemoglobin Modifier, RSR13, in Healthy Volunteers
11th Annual Meeting, AAPS, Seattle, WA, October 27-31, 1996.
Pharm Res 13 (9): S-115 (1996).
47. Venitz, J., Slattum, P.W., Gerber, M., Abraham, D. Pharmacokinetics of Escalating IV Doses of an Allosteric Hemoglobin Modifier, RSR13, in Healthy Volunteers
11th Annual Meeting, AAPS, Seattle, WA, October 27-31, 1996.
Pharm Res 13 (9): S-479 (1996).
48. Venitz, J., Joshi, G., Abraham, D. *In-Vitro* Human Plasma Protein and RBC Binding of Allosteric Modifiers of Hemoglobin
11th Annual Meeting, AAPS, Seattle, WA, October 27-31, 1996.
Pharm Res 13 (9): S-421 (1996).

49. **Sathe, P.M., Venitz, J., Lesko, L.** Evaluation of the Truncated AUC Parameter in the Assessment of Bioequivalence of Drugs with Long Half-Lives
(Selected for PPDM Podium Presentation) 11th Annual Meeting, AAPS, Seattle, WA, October 27-31, 1996.
Pharm Res 13 (9): S-488 (1996).
50. **Ghosh, R., Venitz, J.** Evaluation of *In-Vivo* Bronchoprotective Ability and Tolerance Development for Albuterol and Formoterol against *In-Vitro* Histamine Challenges in Guinea Pigs
11th Annual Meeting, AAPS, Seattle, WA, October 27-31, 1996.
Pharm Res 13 (9): S-443 (1996).
51. **Ramchandani, V.A., Venitz, J.** Pharmacokinetic-Pharmacodynamic Relationship for Different IV Infusion Regimens of Ethanol in Healthy Young Subjects
(Selected for AAPS CS/PPDM Graduate Research Symposium Award) 11th Annual Meeting, AAPS, Seattle, WA, October 27-31, 1996.
Pharm Res 13 (9): S-517 (1996).
52. **Venitz, J., Slattum, P.W., Gerber, M., Abraham, D.** Pharmacokinetic-Pharmacodynamic Modeling of the Effects of an Allosteric Hemoglobin Modifier, RSR13, in Healthy Young Volunteers
98th Annual Meeting, ASCPT, San Diego, CA, March 5-7, 1997.
Clin Pharmacol Ther 61 (2): 154 (1997).
53. **Learned-Coughlin, S.M., Venitz, J.** Pharmacokinetic-Pharmacodynamic Modeling of the Paradoxical Effect of Scopolamine on Heart Rate in Healthy Young Females
98th Annual Meeting, ASCPT, San Diego, CA, March 5-7, 1997.
Clin Pharmacol Ther 61 (2): 233 (1997).
54. **Learned-Coughlin, S.M., Venitz, J.** Central versus Peripheral Effects of IV Scopolamine in Healthy Young Women
98th Annual Meeting, ASCPT, San Diego, CA, March 5-7, 1997.
Clin Pharmacol Ther 61 (2): 178 (1997).
55. **Slattum, P.W., Ramchandani, V.A., Venitz, J.** Gender Differences in Ethanol-Induced Impairment in Young Healthy Volunteers
98th Annual Meeting, ASCPT, San Diego, CA, March 5-7, 1997.
Clin Pharmacol Ther 61 (2): 183 (1997).
56. **Learned-Coughlin, S.M., Venitz, J.** Pharmacokinetic-Pharmacodynamic Relationship for Scopolamine in Healthy Male and Female Volunteers: Effects on Psychometric Performance, Subjective-Rate Sedation, Saliva Flow and Heart Rate
(Best Poster Award) Annual Eastern Regional AAPS Meeting, June 9-10, 1997, New Brunswick, NJ.
57. **Learned-Coughlin, S.M., Mont, R.M., Wesnes, K.A., Venitz, J.** CNS Pharmacodynamics of Scopolamine in Healthy Young Male and Female Volunteers
Annual Meeting, British Association of Psychopharmacology, Cambridge, UK, July 13-17, 1997.
J Psychopharmacol 11 Suppl: A58 (1997).
58. **Dvorchik B.H., Martin, R., Venitz, J.** Pharmacokinetics of GEM-91 in HIV Patients Following Single and Multiple Dosing
Annual Meeting, ACCP, Phoenix, AZ, September 24-27, 1997.
J Clin Pharmacol 37: 877, A83 (1997).
59. **Hong, J.D., Slattum, P.W., Venitz, J.** Pharmacodynamics of Scopolamine in Healthy Elderly Volunteers: A Pilot Study For Evaluating the Scopolamine Challenge in Early Clinical Drug Development
19th Annual Undergraduate Research Seminar, Morgantown, WV, October 18-19, 1997.
60. **Kavanagh, B.D., Khandelwal S.R., Schmidt-Ullrich, R.K., Roberts, J.D., Pearlman A.D., Shaw, E.G., Venitz, J., Gerber, M.J.** A Phase Ib Study to Evaluate Repeated Daily Intravenous Doses of RSR13 Administered to Cancer Patients Receiving Concurrent Radiation Therapy
39th Annual Meeting, ASTRO, Orlando, FL, October 19-22, 1997.
Int J Radiat Oncol Biol Phys 39 (2)S: 330 (1997).
61. **Jagannathan, V., Venitz, J.** Development and Validation of a Radioreceptor Assay (RRA) for the 5-HT_{1A}-Agonists, Buspirone and 1-PP
12th Annual Meeting, AAPS, Boston, MA, November 2-6, 1997.
Pharm Res XX (X): XX (1997).
62. **Venitz, J., Slattum P., Gerber M.** Pharmacokinetic/Pharmacodynamic Modeling of the Effects of an Allosteric Hemoglobin Modifier, RSR13, in Humans - Assessment of Plasma Protein Binding and Red Blood Cell Partitioning *Ex-Vivo* and Validation of Clinically Relevant Surrogate Endpoint
Scientific Symposium "Modeling and Simulation of Clinical Trials in Drug Development and Regulation", Georgetown CDDS,

Herndon, VA, November 10-11, 1997.

63. Kavanagh, B.D., Amir, C., Lin, P.-S., Schmidt-Ullrich, R.K., Venitz, J. Vessel pO₂ Boundary Conditions and Optimal p₅₀ Increase for Radiosensitization via Reduction of Hemoglobin-Oxygen Affinity
Tenth International Conference on Chemical Modifiers of Cancer Treatments, Clearwater, FL, January 1998.
IROPB
64. Venitz, J., Slattum, P.W., Wahr, J.A., Gerber, M.J. PK/PD Modeling of the Effects of an Allosteric Hemoglobin Modifier, RSR13, in Surgery Patients Receiving General Anesthesia
99th Annual Meeting, ASCPT, New Orleans, LA, March 30-April 1, 1998.
Clin Pharmacol Ther 63 (2): 233 (1998).
65. Learned-Coughlin, S.M., Putcha, L., Ramanathan, R., Venitz, J. Pharmacokinetics of Intravenous Scopolamine in Healthy Young Male and Female Volunteers
99th Annual Meeting, ASCPT, New Orleans, LA, March 30-April 1, 1998.
Clin Pharmacol Ther 63 (2): 230 (1998).
66. El-Tahtawy, A., Grevel, J., Venitz, J., Karkowsky, A., Parekh, A., Taylor, A.A. Dual Effect Pharmacokinetic/Pharmacodynamic Modeling of Intravenous Fenoldopam in Moderate Hypertensive Patients
99th Annual Meeting, ASCPT, New Orleans, LA, March 30-April 1, 1998.
Clin Pharmacol Ther 63 (2): 163 (1998).
67. Paiblr, S.A.G., Soine, W.H., Thomas, D.F., Venitz, J., Fisher, R.A. N-Glycosylation of Phenobarbital Using Human Liver Microsomes
26th National Medicinal Chemistry Symposium, Richmond, VA, June 14-18, 1998.
68. Venitz, J., Townsend, R., Steffen, R. Effect of P.O. Probenecid on IV RSR13 Pharmacokinetics and Pharmacodynamics in Cynomolgus Monkeys
13th Annual Meeting, AAPS, San Francisco, CA, November 15-18, 1998.
Pharm Sci 1 (1): S-623 (1998).
69. Sathe, P., Venitz, J., Lesko, L., Williams, R. Utility of the C_{max} Measure in Assessing Bioequivalence: Supportive Evidence
13th Annual Meeting, AAPS, San Francisco, CA, November 15-18, 1998.
Pharm Sci 1 (1): S-499 (1998).
70. Al-Habet, S., Ibrahim, S., Baweja, R., Venitz, J. Effect of Renal Disease on the Disposition of Highly Metabolized Oral Drugs
13th Annual Meeting, AAPS, San Francisco, CA, November 15-18, 1998.
Pharm Sci 1 (1): S-465 (1998).
71. Yuan, R., Venitz, J. Disposition of a Highly Metabolized Drug in Renally Impaired Patients
13th Annual Meeting, AAPS, San Francisco, CA, November 15-18, 1998.
Pharm Sci 1 (1): S-467 (1998).
72. Venitz, J., Liard, J.F., Hackman, J. Pharmacokinetics and Pharmacodynamics of Escalating, Single IV Doses of a Synthetic Allosteric Hemoglobin Modifier, RSR13, in Patients with Stable Effort Angina
100th Annual Meeting, ASCPT, San Antonio, TX, March 18-20, 1999.
Clin Pharmacol Ther 65 (2): 151 (1999).
73. Learned-Coughlin, S.M., Venitz, J. Novel PK/PD Model Permits Estimation of In-Vivo Muscarinic Receptor Subtype Affinities for Scopolamine
100th Annual Meeting, ASCPT, San Antonio, TX, March 18-20, 1999.
Clin Pharmacol Ther 65 (2): 168 (1999).
74. Hong, J.D., Slattum, P.W., Learned-Coughlin, S.M., Wesnes, K., Venitz, J. Central versus Peripheral Effects of IV Bolus Scopolamine in Healthy Young and Elderly Females
100th Annual Meeting, ASCPT, San Antonio, TX, March 18-20, 1999.
Clin Pharmacol Ther 65 (2): 191 (1999).
75. Hermening, A., Venitz, J. Development and Validation of a HPLC Assay for RSR13 and its Acylglucuronide in Preclinical and Clinical Biological Samples
Tenth International Symposium on Pharmaceutical and Biomedical Analysis, Washington, DC, May 9-12, 1999.
76. Hermening, A., Venitz, J. In-Vitro Pharmacokinetics of the Allosteric Hemoglobin Modifier, RSR13, and its Acyl-Glucuronide
Submitted, 14th Annual Meeting, AAPS, New Orleans, LA, November 14-18, 1999.
77. Venitz, J., Yuan, R. Effect of Chronic Renal Failure on the Systemic Pharmacokinetics of Hepatically Metabolized Drugs
Submitted, 14th Annual Meeting, AAPS, New Orleans, LA, November 14-18, 1999.

78. Yuan, R., Venitz, J. Chronic Renal Failure Affects the Disposition of Hepatically Metabolized Drugs
Submitted, 14th Annual Meeting, AAPS, New Orleans, LA, November 14-18, 1999.
79. Hermening, A., Venitz, J. *In-Vitro* Glucuronidation of RSR13: Prediction of *In-Vivo* Intrinsic Hepatic Clearance and Metabolic Interaction with Probenecid
In preparation, 101st Annual Meeting, ASCPT, Los Angeles, CA, March 15-17, 2000.

TECHNICAL REPORTS

1. Venitz, J., Deans, K. Ascending Single Dose Safety and Tolerance Study of DuP-697 in Healthy Male Volunteers (1DU01), Clinical Summary Report, Dupont-Merck, Wilmington, DE, March, 5, 1993.
2. Venitz, J., Ramchandani, V. Pharmacokinetic Analysis Report for A Double-Blind, Placebo-Controlled, Rising-Dose Study of Single, Oral Doses of NE-10064 to Determine Safety and Tolerance in Normal Volunteers, Final Report, Norwich Eaton/Proctor and Gamble, Cincinnati, OH, March 10, 1993.
3. Venitz, J., Jagannathan, V. Pharmacokinetic Analysis Report for A Double-Blind, Placebo-Controlled, Rising-Dose Study of the Safety and Tolerance of Multiple Oral Doses of NE-10064 in Normal Volunteers, Final Report, Norwich Eaton/Proctor and Gamble, Cincinnati, OH, April 27, 1993.
4. Venitz, J., Ramchandani, V. Pharmacokinetic Analysis Report for A Double-Blind, Placebo-Controlled Study of Single, Intravenous Doses of NE-10064 to Determine Safety and Tolerance in Normal Volunteers, Final Report, Norwich Eaton/Proctor and Gamble, Cincinnati, OH, May 18, 1993.
5. Venitz, J. Predinical *In-Vitro* and *In-Vivo* Pharmacokinetic/Pharmacodynamics of RSR-13 in Rats, Preliminary Report, Hemotech (Allos Therapeutics Inc.), December 10, 1993.
6. Venitz, J. Clinical Report: A Double-Blind, Placebo-Controlled, Rising Dose Study of Single, Oral Doses of NE-10064 to Determine Safety and Tolerance in Normal Volunteers (1NR01), Final Report, Norwich Eaton/Proctor and Gamble, Cincinnati, OH, May 20, 1994.
7. Venitz, J. Pharmacokinetics of an Escalating Single-Dose Study with IV Infusions of RSR-13 in Dogs (2W18), Preliminary Report, Allos Therapeutics Inc, February 24, 1995.
8. Venitz, J. Pharmacokinetics of an Escalating Single-Dose Study with IV Infusions of RSR-13 in Rats (TSI 2X05), Preliminary Report, Allos Therapeutics Inc., April 11, 1995.
9. Venitz, J., Slattum, P.W. Pharmacodynamic Analysis: 14-Day Repeated-Dose IV Infusion Study with RSR13 in Beagle Dogs (TSI 2W47), Final Report, Allos Therapeutics Inc., June 8, 1995.
10. Venitz, J. Predinical Pharmacokinetics and Pharmacodynamics of RSR13, Final Summary Report (Part of the IND submission), Allos Therapeutics Inc., May 29, 1995.
11. Venitz, J., Jagannathan, V., Ramchandani, V. Pharmacodynamic Analysis of the EEG Effects of Single-Dose Infusions with CP-101,606 in Normal Male Volunteers, Pfizer Inc., Final Report, Pfizer Central Research (4PF08, 5PF02), Part I, January 5, 1996; Part II, February 11, 1996.
12. Venitz, J., Slattum, P.W. A Phase I Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Ascending Single Intravenous Doses of RSR13 in Healthy Volunteers (HV-001), Final Noncompartmental Pharmacokinetic Analysis Report, Allos Therapeutics Inc., February 12, 1996.
13. Venitz, J., Quagliata, S., Langton, D., Gerber, M., A Phase I Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Ascending Single Intravenous Doses of RSR13 in Healthy Volunteers (HV-001), Final Study Report, Allos Therapeutics Inc., October 10, 1996.
14. Venitz, J. Pharmacodynamic Modeling of the Effects of Albuterol Aerosol in Humans to Assess Bioequivalence in a Pilot Study, Preliminary Report, Kos Pharmaceuticals, November 25, 1996.
15. Venitz, J. Pharmacokinetic Modeling of Steady-State Concentrations of GEM-91 after Escalating Long-Term Infusions to HIV-Positive Patients (91-007), Preliminary Report, Hybridon Inc., June 4, 1996; Final Report, Hybridon Inc., January 5, 1997.
16. Venitz, J. Pharmacokinetic Modeling of GEM-132 in Ocular Tissues after Intravitreal Injection, Preliminary Report, Hybridon Inc., July 7, 1997.
17. Venitz, J. Pharmacokinetic/Pharmacodynamic Modeling of the Effects of a Single Intravenous Infusion of RSR13 in Cynomolgus Monkeys With and Without Pretreatment with Oral Probenecid (3-G14), Preliminary Report, Allos Therapeutics Inc.,

October 6, 1997.

18. Venitz, J., Slattum P.W. Pharmacokinetic/Pharmacodynamic Modeling of the Effects of Escalating Single Intravenous Doses of RSR13 in Elective Surgery Patients Undergoing General Anesthesia (SBL-010), Final Study Report, Allos Therapeutics Inc., February, 28, 1998.
19. Hermening, A., Venitz, J. Standard Operating Procedures for the Determination of RSR13 and RSR13-Acyl Glucuronide in Urine and Plasma Using HPLC, Final Report, Allos Therapeutics Inc., June 23, 1999.
20. Venitz, J. Cowley, S. Pharmacokinetics of IV Buprenorphine in Healthy Volunteers and Patients with Chronic Hepatic Impairment (BP970112), Final Report, Purdue-Pharma/Clinical Development Associates, Richmond, VA, July 29, 1999.
21. Venitz, J., Hackman, J., Liard, J.F. Pharmacokinetic/Pharmacodynamic Modeling of the Effects of Sequential Escalating Single Intravenous Doses of RSR13 in Patients with Stable Effort Angina (CV-020), Final Report, Allos Therapeutics Inc., in preparation (1999).
22. Venitz, J. *In-Vitro* Human Plasma Protein and RBC Binding of RSR13 (ADC-1522), Final Report, Allos Therapeutics Inc., in preparation (1999).
23. Venitz, J. Pharmacokinetic/Pharmacodynamic Modeling of the Effects of Escalating Single Intravenous Doses of RSR13 in Healthy Young Male and Female Volunteers (HV-001), Final Report, Allos Therapeutics Inc., in preparation (1999).
24. Venitz, J. Pharmacokinetic/Pharmacodynamic Modeling of the Effects of Escalating Repeated Intravenous Doses of RSR13 in Patients Receiving Concurrent Radiation Therapy (RT-002), Preliminary Report, Allos Therapeutics Inc., in preparation (1999).

BOOK REVIEWS

1. Derendorf, H., Venitz, J. J. Am. Chem. Soc. 109 (2):293 (1987).
2. Venitz, J., Garrett, E.R. American Scientist (1988).

SCIENTIFIC/TEACHING SOFTWARE DEVELOPMENT

1. Venitz, J.
Pharmacokinetic/Pharmacodynamic Simulation Programs Using Spreadsheets (Version 1.0)
Introduced into Public Domain, October 1991.
2. Venitz, J.
Pharmacokinetic/Pharmacodynamic Simulation Programs Using Spreadsheets (Version 1.1)
Updated/Upgraded into Public Domain, August 1994.
3. Venitz, J.
Pharmacokinetic/Pharmacodynamic Modeling Programs Using Scientist[®] (Version 1.0)
Introduced into Public Domain, February 1997.
4. Venitz, J.
Pharmacokinetic/Pharmacodynamic Simulation Spreadsheets (Version 2.0)
Updated/Upgraded for Public Domain, August 1998.

GRANTS AND CONTRACTS

PRINCIPAL INVESTIGATOR

1. Venitz, J., ~~_____~~
Pharmacokinetics and Biopharmaceutics Studies of Hymecromone (Cantabiline[®]) in Man
Liphar Chemicals Inc., New York, NY, 1986,
~~_____~~ completed.
2. Venitz, J., ~~_____~~
Safety and Pharmacokinetics of Multiple-Dose BID Administration of Tandoospirone (60 mg, 90 mg and 120 mg total daily dose)
in Healthy Male Volunteers
Pfizer Pharmaceuticals, New York, NY, 1990,
~~_____~~ completed.

3. Venitz, J., Comparative Bioavailability of Two Glipizide GITS Formulations and Glipizide Conventional Tablet in Normal Volunteers
Pfizer Pharmaceuticals, New York, NY, 1990,
completed.
4. Venitz, J., Penetration of Cefprozil into Human Breast Milk; a Pharmacokinetic Study (Graduate Research Project,)
Bristol Myers, Syracuse, NY, 1990,
completed.
5. Venitz, J., Penetration of Cefepime (BYM-28142) into Human Breast Milk; a Pharmacokinetic Study
Bristol Myers, Syracuse, NY, 1990,
completed.
6. Venitz, J., Pharmacokinetics and Pharmacodynamics of Two Different Glipizide Dosage Forms after Multiple Doses in Patients with NIDDM
Pfizer Pharmaceuticals, New York, NY, 1990,
completed.
7. Venitz, J., Single Oral Dose Safety and Tolerance Study of CGS-18416A
Ciba Geigy Corp., Ardsley, NY, 1990,
completed.
8. Venitz, J., Bioavailability of the Glipizide GITS 20 mg Tablet in Normal Healthy Volunteers when Administered under Fed and Fasting Conditions (Pharm. D. Research Project,
Pfizer Pharmaceuticals, New York, NY, 1990,
completed.
9. Venitz, J., Phase I Study to Assess the Feasibility and Ability to Quantitatively Differentiate between Central versus Peripheral Effects of Different Doses of Acetylcholinesterase Inhibitors Using Neostigmine as a Prototype (Pharm. D. Research Project,
Pfizer, Groton, CT, 1991,
completed.
10. Venitz, J., Ascending Single Dose Safety and Tolerance Study of DuP 697 in Healthy Male Volunteers (1DU01)
DuPont Merck Pharmaceutical Company, Newark, DE, 1991-1992,
(part I)
(part II), completed.
11. Venitz, J., A Double-Blind, Placebo-Controlled, Rising-Dose Study of Single, Oral Doses of NE-10064 to Determine Safety and Tolerance in Normal Volunteers (1NR01)
Norwich Eaton Pharmaceuticals, Norwich, NY, 1991,
completed.
12. Venitz, J., Pharmacokinetic-Pharmacodynamic Relationship for Ethanol in Healthy Subjects
Part I Assessment of Electroencephalography (EEG), Psychometric Tests and Mood Scales: Effect of Dose and Rate of Ethanol Ingestion in Healthy Male Subjects (Graduate Research Project,)
Finalist, Forbes Day of Excellence in Graduate Research, 1996)
Personal Research Funds (J. Venitz); partial support: NIH Grant M01 R00065, Cognitive Drug Research, Priory Court, UK, 1991-1992,
completed.
13. Venitz, J., Effect of Different Doses and Dose Rates of Bronchoconstricting and Bronchodilating Agents in the Isolated Perfused Guinea Pig Lung Model
Part I In-Vitro Effects and Tolerance Development to Histamine Challenges
Part II Comparison of In-Vitro and In-Vivo Bronchoprotective Activity and Tolerance Development of α -Agonists, Salmeterol and Formoterol
Part III In-Vitro Effects of Substance P on Airway Bronchoconstriction and Blockade by the NK₁-receptor antagonist, CP-99,994

- (Graduate Research Project,
Intramural Departmental Funds/Personal Research Funds (J. Venitz), 1991-1996,
— completed.
14. **Venitz, J.,** Phase I Double-Blind Placebo-Controlled Evaluation of the Safety, Tolerantion and Pharmacokinetics of CP-99,994 Following Escalating Single IV Infusions in Healthy Male Subjects (1PF05)
Pfizer, Groton, CT, 1991-1992,
— (part I)
— (part II)
— (part III), completed.
 15. **Venitz, J** Phase I Double-Blind Placebo-Controlled Evaluation of the Safety, Tolerance and Pharmacokinetics of Escalating Single Oral Doses of CP-99,994 in Healthy Male Subjects (2PF04)
Pfizer, Groton, CT, 1992,
— completed.
 16. **Venitz, J.,** Single Oral Tolerance and Pharmacokinetics of MDL 26,024GO (1MA02)
Marion Merrell Dow, Cincinnati, OH, 1992,
— completed.
 17. **Venitz, J.,** Phase I Study to Assess Various Psychological Tests After the Introduction of Scopolamine and Physostigmine to Healthy Male Volunteers (2PF09)
Pfizer, Groton, CT, 1992,
— completed.
 18. **Venitz, J.,** Pharmacokinetic/Pharmacodynamic Modeling of the CNS Effects of Antidepressants on the Stimulated and Unstimulated Serotonergic System in Healthy Volunteers: Comparison of Effects on the EEG, Neuroendocrine Responses, Behavioral Tests and Mood Scales
Part I Clinical Assessment of Central 5-HT Function Using Intravenous L-Tryptophan in Normal, Healthy Volunteers
(Graduate Research Project,
Personal Research Funds (J. Venitz), 1991-1995,
— funded, implementation stopped due to FDA's clinical hold on IV L-tryptophan.
 19. **Venitz, J.,** Phase I Double-Blind, Placebo Controlled Evaluation of the Effects of CP-99,994 on Responses to Intravenous Infusion and Intradermal Injection of Substance P in Healthy Male Subjects (2PF11)
Pfizer, Groton, CT, 1992,
— completed.
 20. **Venitz, J.,** Phase I Open Evaluation of the Effects of CP-99,994 on Responses to Intravenous Infusion of Substance P in Healthy Male Subjects (3PF01)
Pfizer, Groton, CT, 1992-1993,
— completed.
 21. **Venitz, J.,** Kinetic and Dynamic Interaction between Dofetilide and Verapamil under Steady-State Conditions in Healthy Volunteers (2PF10)
Pfizer, Groton, CT, 1993,
— completed.
 22. **Venitz, J.,** Phase I Study to Assess the Safety, Tolerantion, Pharmacokinetics and Pharmacodynamics of Single, Escalating Doses of CP-118,954 in Healthy, Normal Volunteers with and without Scopolamine Challenge (2PF12)
Pfizer, Groton, CT, 1992-1993,
— (part I)
— (part II), completed.
 23. **Venitz, J** Phase II, Randomized, Double-Blind, Placebo Controlled, Multiple Crossover Study of Single Doses of CP-118,954 in Alzheimer's Disease (3PF04)
Pfizer, Groton, CT, 1993,

- not funded.
24. Venitz, J., Pharmacokinetic/Pharmacodynamic Modeling of the CNS Effects of Antidepressants on the Stimulated and Unstimulated Serotonergic System in Healthy Volunteers: Comparison of Effects on the EEG, Neuroendocrine Responses, Behavioral Tests and Mood Scales
Part II Clinical Assessment of Central 5-HT Function Using Single Oral Doses of Buspirone in Normal, Healthy Volunteers
(Graduate Student Project,
(unrestricted grant) Pfizer, Groton, CT; partial support: Cognitive Drug Research, Reading, UK, 1994-1995,
completed.
 25. Venitz, J., Multiple Oral Dose Tolerance and Pharmacokinetic Study of MDL 26,024GO (3MA01)
Marion Merrell Dow, Cincinnati, OH, 1993,
completed.
 26. Venitz, J., Double-Blind, Placebo-Controlled Evaluation of the Clinical Pharmacology of CP-122,721 Following Escalating Single Oral Doses in Healthy Male Subjects (3PF03)
Pfizer, Groton, CT, 1993-1994,
(part I)
(part II), completed.
 27. Venitz, J., Double-Blind, Placebo-Controlled Evaluation of the Clinical Pharmacology of CJ-11,975 Following Escalating Single Oral Doses in Healthy Male Subjects (3PF06)
Pfizer, Groton, CT, 1993-1994,
(part I)
(part II)
(part III), completed.
 28. Venitz, J., Double-Blind, Placebo-Controlled Evaluation of the Clinical Pharmacology of CP-101,606 Following Intravenous Infusions of Escalating Doses in Healthy Male Subjects (3PF05)
Pfizer, Groton, CT, 1993,
not funded.
 29. Venitz, J., Phase I Open Evaluation of the Clinical Pharmacology of CP-122,721 Administered as a Solution in the Fasted State and as a Capsule in the Fasted and Postprandial States in Healthy Male Subjects (3PF15)
Pfizer, Groton, CT, 1993,
completed.
 30. Venitz, J., Phase I Double-Blind, Placebo-Controlled Study of the Clinical Pharmacology of Multiple Doses of CP-122,721 in Healthy Male Subjects (3PF14)
Pfizer, Groton, CT, 1994,
(part I)
(part II), completed.
 31. Venitz, J., Phase I, Parallel-Group, Placebo-Controlled Study in Assessing the Clinical Pharmacology of Single Escalating Doses of CP-122,817 in Healthy Male Subjects (4PF02)
Pfizer, Groton, CT, 1994,
not funded.
 32. Venitz, J., Phase I Double-Blind, Placebo-Controlled Evaluation of the Safety, Tolerantion, and Pharmacokinetics of CP-116,517 Following Escalating Single Intravenous Infusions in Healthy Male Subjects (3PF17)
Pfizer, Groton, CT, 1994,
(part I)
(part II), completed.
 33. Venitz, J., Phase I Double-Blind, Placebo-Controlled Study of the Clinical Pharmacology of Multiple Doses of CJ-11,975 in Healthy Male Subjects (4PF07)
Pfizer, Groton, CT, 1994,

- _____ completed.
34. Venitz, J., _____
Phase I Open Evaluation of the Clinical Pharmacology of CJ-11,975 Administered as a Solution in the Fasted State and as a Capsule in the Fasted and Postprandial States in Healthy Male Subjects (4PF06)
Pfizer, Groton, CT, 1994,
_____ not funded.
 35. Venitz, J., _____
Phase I, Single Dose, Double-Blind, Placebo-Controlled Evaluation of CP-101,606 Following Intravenous Infusion of Escalating Doses in Healthy, Male Volunteers (4PF08)
Pfizer, Groton, CT, 1994-1995,
_____ completed.
 36. Venitz, J., _____
A Phase I, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety, Tolerantion, and Pharmacokinetics of Single Escalating Doses of CP-247,106 in Healthy, Male Subjects (4PF09)
Pfizer, Groton, CT, 1994-1995,
_____ not funded.
 37. Venitz, J., _____
Effect of Four-Week Hospitalization in Phase I Studies on the Orthostatic Regulation in Healthy, Male Volunteers (Undergraduate Research Project, K. Kress)
Personal research funds (J. Venitz), 1994-1995,
_____ completed.
 38. Venitz, J., _____
Phase I, Double-Blind, Placebo-Controlled Evaluation of CP-101,606 Following 24-Hour Intravenous Infusions in Healthy, Male Volunteers (5PF02)
Pfizer, Groton, CT, 1995,
_____ (part I) completed,
_____ (part II), completed.
 39. Venitz, J., _____
A Phase I Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Ascending Single Intravenous Doses of RSR13 in Healthy Volunteers (5AO01)
Allos Therapeutics Inc., Denver, CO; partial support: Center for Innovative Technology (CIT), Herndon, VA, 1995,
_____ completed.
 40. Venitz, J., _____
Phase I Open Study to Determine the Absolute Bioavailability of CP-101,606 in Healthy, Male Volunteers (5PF05)
Pfizer, Groton, CT, 1995-1996,
_____ completed.
 41. Venitz, J., _____
Phase I Double-Blind, Placebo-Controlled Evaluation of the Safety, Tolerantion, and Pharmacokinetics of CP-316,311 Following Escalating Single Doses in Healthy Male Subjects (5PF06)
Pfizer, Groton, CT, 1996,
_____ completed.
 42. Venitz, J., _____
Phase I Double-Blind, Placebo-Controlled Study of the Clinical Pharmacology of Escalating Multiple Doses of CP-316,311 in Healthy Male Volunteers (6PF01)
Pfizer, Groton, CT, 1996,
_____ completed.
 43. Venitz, J., _____
Phase I Double-Blind Parallel Study of the Effects of Diphenhydramine, Diazepam and Placebo on Fear-Potentiated Acoustic Startle Reflex in Healthy Subjects (5PF04)
Pfizer, Groton, CT, 1995,
_____ not funded.
 44. Venitz, J., _____
A Phase I Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Continuous Intravenous Infusions of RSR13 in Healthy Volunteers (7AO01)
Allos Therapeutics Inc., Denver, CO, 1997-1998,
_____ completed.

45. Venitz, J., Phase I Study to Evaluate the Effect of CP-424,391 on Autonomic Reflexes after Single Dose Administration to Healthy, Young, Male Subjects (7PF01)
Pfizer, Groton, CT 1997-1998,
not funded.
46. Venitz, J., Evaluation of the Human Metabolism of the Synthetic Allosteric Hemoglobin Modifier, RSR13, In-vitro and In-vivo
Allos Therapeutics Inc., Denver, CO, partial support: Center for Innovative Technology (CIT), Herndon, VA, 1998-1999,
completed.
47. Venitz, J., A Pilot Feasibility Study to Assess the Effects of Single Escalating Intranasal Doses of Nicotine on Neuroendocrine, Cognitive and Behavioral Function in Healthy Young Smokers and Nonsmokers
VCU Small Grants Program for Drug Abuse Research, 1999.

CO-INVESTIGATOR

1. Venitz, J., Comparative Bioavailability of Calan(SR) Manufactured by Searle and Knoll
Searle, 1988,
completed.
2. Venitz, J., The Effect of Exercise and Food on the Pharmacokinetics of Oral Propranolol (Graduate Research Project, Intramural Funds (), 1989-1990,
completed.
3. Venitz, J., Gepirone Site of Gastrointestinal Absorption in Man
Pfizer Pharmaceuticals, New York, NY, 1989,
completed.
4. Venitz, J., The Effect of Co-Administration of Cyclosporine (Sandimmune, Sandoz) and Misoprostol (Cytotec) on the Blood Concentration of Cyclosporine after a Single Dose in Healthy Male Subjects (Pharm. D. Research Project, Searle, Skokie, IL, 1989,
completed.
5. Venitz, J., A Single-dose Proportionality and Bioequivalence Study of Lamotrigine in Healthy Male Volunteers
Burroughs Wellcome, Research Triangle Park, NC, 1989,
completed.
6. Venitz, J., Effect of Misoprostol on the Single-Dose and Multiple-Dose Pharmacokinetics of Diclofenac in Elderly Subjects (Pharm. D. Research Project, Searle, Skokie, IL, 1989,
completed.
7. Venitz, J., Pharmacokinetics and Pharmacodynamics of IV Guanfacine at Three Steady-State Concentrations in Normal Volunteers (Graduate Research Project, Intramural Funds (C. Lathia), partial support: NIH Grant M01 R00065, 1989-1990,
completed.
8. Venitz, J., The Effect of Serum Glucose and Insulin on the Metabolic Disposition of Amobarbital in Humans (Graduate Research Project, Intramural Funds (), partial support: NIH Grant M01 R00065, 1989-1990,
completed.
9. Venitz, J., A Study to Determine the Effect of Food on the Bioavailability of Torsemide Tablets in Healthy Subjects
Boehringer Mannheim, Rockville, MD, 1990,
completed.

10. Venitz, J.
The Pharmacokinetics of Enisoprost when Co-Administered with Diclofenac
Searle, Skokie, IL, 1990,
completed.
11. Venitz, J.
A Single-Dose Pharmacokinetic Study of Gabapentin in Subjects with Various Degrees of Renal Function (Pharm. D. Research Project,
Parke Davis, Ann Arbor, MI, 1990,
completed.
12. Venitz, J.
Effect of Enisoprost on Cyclosporine Pharmacokinetics in Healthy Male Subjects
Searle, Skokie, IL, 1990,
completed.
13. Venitz, J.
Glipizide Absorption from Different Sites of the Gastrointestinal Tract
Pfizer Pharmaceuticals, New York, NY, 1989,
completed.
14. Venitz, J.
Tandospirone Absorption from Different Sites of the Gastrointestinal Tract in Humans
Pfizer Pharmaceuticals, New York, NY, 1989,
completed.
15. Venitz, J.
Single Dose Bioequivalence Study of Ibuprofen 400 mg Tablets in Healthy Male Volunteers
Danbury, New York, NY, 1989,
completed.
16. Barr, W.H., Venitz, J., Smith,
Influence of Gastrointestinal Site on Albuterol Absorption
Schering Plough, Kenilworth, NJ, 1990,
completed.
17. Venitz, J.
Misoprostol Pharmacokinetics in Patients with Hepatic Impairment
Searle, Skokie, IL, 1990-1992,
completed.
18. Venitz, J.
The Effect of Oral Recainam on Serum Digoxin Concentrations
Wyeth Ayerst, Philadelphia, PA, 1990-1991,
partially completed.
19. Venitz, J.
Kinetics of Diclofenac and Its Metabolites in Normal Subjects and in Graded Renal Insufficient Patients
Ciba Geigy Corp., Ardsley, NY, 1990-1992,
completed.
20. Venitz, J.
Comparative Pharmacokinetic Study in Epileptic Patients Receiving Tegretol in the Form of Commercial and OROS Dosage Forms
Ciba Geigy Corp, Ardsley, NY, 1990-1991,
completed.
21. Venitz, J.
The Absolute Bioavailability and Pharmacokinetics of Transnasal Butorphanol in Normal and Hepatically Impaired Subjects
Bristol-Myers-Squibb, Syracuse, NY, 1990-1991,
completed.
22. Venitz, J.
An Evaluation of the Effect of Chemotherapy on the Pharmacokinetics of Oral Ondansetron
Glaxo Inc., Research Triangle Park, NC, 1990-1992,
completed.
23. Venitz, J.

24. Venitz, J.
A Single Dose Pharmacokinetic Study of Procaterol Hydrochloride in Subjects with Various Degrees of Renal Function
Parke-Davis Pharmaceutical Research Division, Ann Arbor, MI, 1990-1993,
completed.
25. Venitz, J.
Double-blind Evaluation to Determine the Influence of Fluvastatin Administration on the Pharmacokinetics of Oral Digoxin in a Patient Population Chronically Receiving Digoxin (Pharm. D. Research Project
Sandoz Pharmaceuticals Corp., East Hanover, NJ, 1990-1991,
completed.
26. Venitz, J.
A Study to Determine the Effect of Tacrine Administration on the Anticoagulant Activity of Warfarin in Patients Taking Warfarin
Parke-Davis Pharmaceuticals, Ann Arbor, MI, 1991-1992,
completed.
27. Venitz, J.
Follow-Up Study on the Effect of Renal Impairment on Acarbose Pharmacokinetics
Miles Inc. Pharmaceutical Division, West Haven, CT, 1991-1993,
partially completed.
28. Venitz, J.
Age-Related Changes in CNS Pharmacodynamics and Pharmacokinetics of Diphenhydramine
Geriatric Drug Therapy Research Institute Award ; partial support: NIH Grant M01 R00065, 1991-1992,
completed.
29. Venitz, J.
Evaluation of Quantitative EEG for Assessment of CNS Stimulant Response
Part I: Reproducibility of Control Responses
Part II: Comparison of Quantitative EEG to Behavioral, Psychological and Neuroendocrine Measures of Response to Dextroamphetamine
(Graduate Research Project, Finalist, Forbes Day of Excellence in Graduate Research, 1993)
Intramural Departmental Funds ; partial support: NIH Grant M01 R00065, 1991-1992,
completed.
30. Venitz, J.
A Comparative Evaluation of the Pharmacokinetics and Pharmacodynamics of CGP 39393, Given As a 30-minute Infusion to Patients with Varying Degrees of Renal Insufficiency and to Subjects with Normal Renal Function (Pharm. D. Research Project,
Ciba-Geigy Corp., Ardsley, NY, 1991-1994,
partially completed.
31. Venitz, J.
Four-week Ascending Double-Blind Multidose Add-On Pharmacokinetic and Tolerability Trial in Male Epileptic Adults with CGP 33101
Ciba-Geigy Corp., Ardsley, NY, 1991,
completed.
32. Venitz, J.
Randomized, Double-Blind, Vehicle-Controlled, Rising Single Dose Tolerance Study of ISIS 2105 in Normal Human Volunteers
Isis Pharmaceuticals, Carlsbad, CA, 1992,
(part I)
(part II), completed.
33. Venitz, J.
Effect of Renal Disease on Systemic ICG Clearance (Pharm. D. Research Project
Intramural Funds ; 1992,
completed.
34. Venitz, J.
Physiologic Pharmacokinetic/Pharmacodynamic Modeling of Acute Tolerance with Continuous Infusion Furosemide in Healthy Young and Elderly Subjects (Graduate Research Project, T. Comstock)

Intramural Funds (T.C. Comstock), 1992-present,
\$ — ongoing.

35. Venitz, J.
A Preliminary Study to Characterize the Safety/Tolerant and the Pharmacokinetic Profile of Single Doses of 250, 500, 1000, 2000 and 4000 mg of Zeolite A in Healthy, Adult Male Subjects
Whitby Research Inc., Richmond, VA, 1992-1993,
completed.
36. Venitz, J.
Comparison of the Degree of and Development of Tolerance to the Psychomotor Effects of Adinazolam Mesylate and Alprazolam after Multiple Dosing (Pharm. D. Research Project)
The Upjohn Company, Kalamazoo, MI, 1992-1993,
completed.
37. Venitz, J.
The Effect of Concurrent Multiple Dose Theophylline Treatment on the Pharmacokinetic and Electrocardiographic Pharmacodynamics of Terfenadine after Multiple Dosing in Normal Female Subjects: A Pilot Study
Marion Merrell Dow, Kansas City, MO, 1993,
not funded.
38. Venitz, J.
In-vitro Effects of MDL 26,024GO on Human Monocytes and Macrophage Function
Marion Merrell Dow, Kansas City, MO, 1993,
not funded.
39. Venitz, J.
Phase I Observer-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Effect of CP-99,219 on the Steady-State Pharmacokinetics of Theophylline in Healthy Subjects
Pfizer, Groton, CT; 1993,
completed.
40. Venitz, J.
Pharmacokinetic-Pharmacodynamic Relationship for Ethanol in Healthy Male Subjects.
Part II Modeling the Development of Tolerance to the Effects of IV Ethanol Administration in Healthy Male and Female Subjects: Effect of Systemic Input Rate and Degree of Ethanol Exposure
(Graduate Research Project; Finalist, Forbes Day of Excellence in Graduate Research, 1996)
Personal research funds (J. Venitz); partial support: NIH Grant M01 R00065; Cognitive Drug Research, Priory Court, UK; 1994-1995,
completed.
41. Venitz, J.
Development of a Pharmacokinetic-Pharmacodynamic Model for the In-vitro Antimicrobial Activity of Antibiotics after Different Exposures
Modeling Time-Kill Curves and Post-Antibiotic Effects
(Graduate Research Project,
Personal research funds (J. Venitz); 1994-1995,
completed.
42. Venitz, J.
A Phase Ib Study to Evaluate the Safety and Tolerance of Multiple Daily Intravenous Doses of RSR13 Administered to Patients Receiving Concurrent Radiation Therapy (RT-002)
Allos Therapeutics, Denver, CO; 1995-1997,
completed.
43. Venitz, J.
Pharmacokinetic-Pharmacodynamic Relationship for Scopolamine after Intravenous Administration to Healthy Young Male and Female Volunteers: Assessment of the Effects of EEG, Psychometric Performance, Sedation Scales, Saliva Flow and Heart Rate
(Graduate Student Project, Finalist, Forbes Day of Excellence in Graduate Research, 1996)
Personal research funds (J. Venitz); partial support: NIH Grant M01 R00065; Cognitive Drug Research, Priory Court, UK; 1995-1996,
completed.
44. Venitz, J.
Age- and Gender-Related Differences in the Sensitivity to Ethanol in Humans
Personal research funds (J. Venitz); partial support: Center for Drug Studies, School of Pharmacy, VCU; NIH Grant M01 R00065; Cognitive Drug Research, Priory Court, UK; 1996-present,

- ~~_____~~ ongoing.
45. ~~_____~~ Venitz, J.
Concentration-Kinetics of the 5-HT_{1A}-Agonist, Buspirone, in Humans Assessed Using a Radioreceptor Assay (RRA): Comparison with Chemical Detection Using GC-MS and Relationship to the Pharmacodynamic CNS Effects
Personal research funds (J. Venitz); 1996-1997,
~~_____~~ completed.
46. ~~_____~~ Venitz, J.
Phase I Trials of Anti-Cancer Agents
RFA: CA-97-001, NIH, NCI; 1997,
~~_____~~ not funded.
47. ~~_____~~ Venitz, J.
Pharmacokinetic-Pharmacodynamic Relationship in Healthy Elderly Volunteers: A Paradigm for Evaluating Cholinergic Agents for Alzheimer's Disease in Early Clinical Drug Development
Personal research funds (J. Venitz); partial support: Center for Drug Studies, School of Pharmacy, VCU; NIH Grant M01 R00065; Cognitive Drug Research, Priory Court, UK; 1996-present,
~~_____~~ ongoing.
48. ~~_____~~ Venitz, J.
Validating Peritonitis Dosing Guidelines in Cyclic Peritoneal Dialysis
Submitted, ASTRA Clinical Research Grant, 1998,
Funded, A.D. Williams Grant, VCU
~~_____~~ ongoing.
49. ~~_____~~ Venitz, J.
Scientific Validation of the Drug Editor Module for the METI HPS
Submitted, Medical Education Technologies Inc., Sarasota, FL, 1998,
~~_____~~ not funded.
50. ~~_____~~ Venitz, J.
Pharmacokinetics and Pharmacodynamics of Temazepam during Simulated Microgravity Conditions
Submitted, NASA, Gravitational Biology and Biomedical Research and Countermeasures Program, Houston, TX, 1998,
~~_____~~ pending.
51. ~~_____~~ Venitz, J.
Age-related Differences in Sensitivity to Ethanol
ACCP Research Award, ACCP Research Institute, Kansas City, MO, 1999
~~_____~~ pending.

EXTRACURRICULAR ACTIVITIES

1974-1975

Nurse Assistant,
Internal Medicine Ward, Knappschafts Krankenhaus Sulzbach/Saar, General Surgery Ward,
Knappschafts Krankenhaus Quierschied/Saar, West Germany, for a total of four months

1976-1978

Foreign Medical Student Advisor,
Universität des Saarlandes, Homburg/Saar, West Germany

1976

Physician Assistant,
General Intensive Care Unit, Clinique S^{te} Thérèse, Luxembourg, Luxembourg, for a total of two months

1977

Student Semester President,
Member, Medical Student Government,
Fachschaft Medizin, Universität des Saarlandes, Homburg/Saar, West Germany

1977-1978

Part-Time Paramedic on the Mobile Medical Emergency Team,
German Red Cross, Homburg/Saar, West Germany

1994-1995

Volunteer Scientist,
Science-By-Mail, Science Museum of Virginia